<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="(http://creativecommons.org/licenses/by/4.0/). Abstract As the outbreak of the new coronavirus (SARS-CoV-2)" exact="infection" post="is spreading globally, great effort is being made to"/>
 <result pre="spreading globally, great effort is being made to understand the" exact="disease" post="pathogenesis and host factors that predispose to disease progression"/>
 <result pre="understand the disease pathogenesis and host factors that predispose to" exact="disease" post="progression in an attempt to find a window of"/>
 <result pre="hyper-inflammatory response has emerged as a key factor in determining" exact="disease" post="severity and mortality. Accumulating clinical observations raised hypotheses to"/>
 <result pre="raised hypotheses to explain why some patients develop more severe" exact="disease" post="while others only manifest mild or no symptoms. So"/>
 <result pre="among other factors, on the frequency of asymptomatic or mildly" exact="symptomatic" post="patients as well as on the testing strategy adopted"/>
 <result pre="proportion of undiagnosed cases. An accurate estimate of the overall" exact="infection" post="fatality is still very difficult to calculate. Recent estimates"/>
 <result pre="However, taking into account the ratio of asymptomatic cases support" exact="infection" post="fatality ratios hovering 0.4â€&quot;0.7% [5]. These figures are lower"/>
 <result pre="support infection fatality ratios hovering 0.4â€&quot;0.7% [5]. These figures are" exact="lower" post="than that of Severe acute respiratory syndrome (SARS) and"/>
 <result pre="hovering 0.4â€&quot;0.7% [5]. These figures are lower than that of" exact="Severe" post="acute respiratory syndrome (SARS) and Middle East respiratory syndrome"/>
 <result pre="0.4â€&quot;0.7% [5]. These figures are lower than that of Severe" exact="acute" post="respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS),"/>
 <result pre="[5]. These figures are lower than that of Severe acute" exact="respiratory" post="syndrome (SARS) and Middle East respiratory syndrome (MERS), which"/>
 <result pre="These figures are lower than that of Severe acute respiratory" exact="syndrome" post="(SARS) and Middle East respiratory syndrome (MERS), which had"/>
 <result pre="that of Severe acute respiratory syndrome (SARS) and Middle East" exact="respiratory" post="syndrome (MERS), which had case fatality rates around 10%"/>
 <result pre="of Severe acute respiratory syndrome (SARS) and Middle East respiratory" exact="syndrome" post="(MERS), which had case fatality rates around 10% and"/>
 <result pre="averaging 0.1%. The reasons why some patients progress to severe" exact="disease" post="while others only manifest with mild or no symptoms"/>
 <result pre="response has clearly emerged as a key factor in determining" exact="disease" post="severity and mortality. As clinical and epidemiologic information on"/>
 <result pre="severity and mortality. As clinical and epidemiologic information on SARS-CoV-2" exact="infection" post="have increased, a better knowledge on the burden of"/>
 <result pre="have increased, a better knowledge on the burden of severe" exact="disease" post="and clinical risk factors associated with disease progression have"/>
 <result pre="burden of severe disease and clinical risk factors associated with" exact="disease" post="progression have emerged. Older age, male gender, and pre-existing"/>
 <result pre="disease progression have emerged. Older age, male gender, and pre-existing" exact="chronic" post="conditions, such as diabetes, obesity, cardiovascular disease, have been"/>
 <result pre="male gender, and pre-existing chronic conditions, such as diabetes, obesity," exact="cardiovascular disease," post="have been observed to be the most significant risk"/>
 <result pre="immune system, as well as of the immune pathology driving" exact="disease" post="progression, may therefore provide opportunities for treatment interventions and"/>
 <result pre="Possible Scenario of Covid-19 Immune Response with Effective Recovery 2.1.1." exact="Viral" post="Entry via ACE2 Binding (Figure 1a I) Both SARS-CoV"/>
 <result pre="is widely expressed in many cells across the body, including" exact="type II" post="alveolar cells (AT2), upper airways cells, endothelial cells, myocardial"/>
 <result pre="cells across the body, including type II alveolar cells (AT2)," exact="upper" post="airways cells, endothelial cells, myocardial cells, proximal tubule cells"/>
 <result pre="myocardial cells, proximal tubule cells of the kidney, ileum and" exact="esophagus" post="epithelial cells, and bladder urothelial cells [13,14,15,16,17]. Coronavirus spike"/>
 <result pre="cells, proximal tubule cells of the kidney, ileum and esophagus" exact="epithelial" post="cells, and bladder urothelial cells [13,14,15,16,17]. Coronavirus spike (S)"/>
 <result pre="cells [13,14,15,16,17]. Coronavirus spike (S) glycoprotein binds to ACE2 initiating" exact="viral" post="entry into host cells. Of note, the affinity of"/>
 <result pre="of ACE2 may facilitate or protect alveolar cells from the" exact="infection" post="is still debated [21]. Binding of the S1 subunit"/>
 <result pre="protein to ACE2 is followed by the fusion of the" exact="viral" post="and cellular membranes mediated by the S2 subunit of"/>
 <result pre="and this may be related to higher prevalence of both" exact="infection" post="and severe disease in males [22,23]. After viral entry"/>
 <result pre="be related to higher prevalence of both infection and severe" exact="disease" post="in males [22,23]. After viral entry into cells, expression"/>
 <result pre="of both infection and severe disease in males [22,23]. After" exact="viral" post="entry into cells, expression of membrane ACE2 is downregulated"/>
 <result pre="angiotensin II in lung tissues and increased stimulation of the" exact="Type 1" post="Angiotensin II Receptor (ATR1), which mediates angiotensin II-induced vascular"/>
 <result pre="Type 1 Angiotensin II Receptor (ATR1), which mediates angiotensin II-induced" exact="vascular" post="permeability and severe acute lung injury [24,25]. Notably, injection"/>
 <result pre="Receptor (ATR1), which mediates angiotensin II-induced vascular permeability and severe" exact="acute" post="lung injury [24,25]. Notably, injection of SARS-CoV S protein"/>
 <result pre="of SARS-CoV S protein in mice is sufficient to worsen" exact="acute" post="lung failure, and this effect is reduced by renin-angiotensin"/>
 <result pre="[26]. All these observations may explain why SARS-CoV-2 primarily causes" exact="pneumonia" post="with vascular injury, differently from influenzavirus, and suggest that"/>
 <result pre="these observations may explain why SARS-CoV-2 primarily causes pneumonia with" exact="vascular" post="injury, differently from influenzavirus, and suggest that higher availability"/>
 <result pre="Nod-like receptor family, pyrin domain-containing 3 (NLRP3) mediated by the" exact="viral" post="3a protein which acts as a potassium ion channel"/>
 <result pre="and this may be a cause of protracted form of" exact="disease" post="requiring readmission to hospital in some patients due to"/>
 <result pre="disease requiring readmission to hospital in some patients due to" exact="gastroenteritis" post="symptoms with persistence of viral RNA in stools after"/>
 <result pre="in some patients due to gastroenteritis symptoms with persistence of" exact="viral" post="RNA in stools after resolution of respiratory symptoms [33]."/>
 <result pre="with persistence of viral RNA in stools after resolution of" exact="respiratory" post="symptoms [33]. Recent findings support a primary role of"/>
 <result pre="after resolution of respiratory symptoms [33]. Recent findings support a" exact="primary" post="role of endothelial cell infection and resulting endotheliitis in"/>
 <result pre="[33]. Recent findings support a primary role of endothelial cell" exact="infection" post="and resulting endotheliitis in Covid-19 pathogenesis, which may lead"/>
 <result pre="organ injury [31]. Endothelial injury may be due to direct" exact="viral infection" post="of endothelial cells as well as to endothelial activation"/>
 <result pre="injury [31]. Endothelial injury may be due to direct viral" exact="infection" post="of endothelial cells as well as to endothelial activation"/>
 <result pre="as to endothelial activation and apoptosis from inflammatory cytokines, especially" exact="tumor" post="necrosis factor alpha (TNFÎ±) [34]. According to recent unpublished"/>
 <result pre="recent unpublished data from autopsies, it has been argued that" exact="vascular" post="damage with peripheral lung microthrombi may be an early"/>
 <result pre="from autopsies, it has been argued that vascular damage with" exact="peripheral" post="lung microthrombi may be an early phenomenon directly linked"/>
 <result pre="lung microthrombi may be an early phenomenon directly linked to" exact="viral infection" post="rather than to the inflammatory reaction. A significant incidence"/>
 <result pre="microthrombi may be an early phenomenon directly linked to viral" exact="infection" post="rather than to the inflammatory reaction. A significant incidence"/>
 <result pre="rather than to the inflammatory reaction. A significant incidence of" exact="disseminated intravascular coagulation" post="and thromboembolism has been also reported. This led to"/>
 <result pre="in hospitalized patients with Covid-19 [35,36]. Overall, the occurrence of" exact="pulmonary" post="vascular (micro)thrombosis and of vascular dysregulation due to angiotensin"/>
 <result pre="hospitalized patients with Covid-19 [35,36]. Overall, the occurrence of pulmonary" exact="vascular" post="(micro)thrombosis and of vascular dysregulation due to angiotensin system"/>
 <result pre="[35,36]. Overall, the occurrence of pulmonary vascular (micro)thrombosis and of" exact="vascular" post="dysregulation due to angiotensin system abnormalities may account for"/>
 <result pre="space ventilation (ventilation of poorly perfused lung), a defective hypoxic" exact="pulmonary" post="vasoconstriction with areas not ventilated but perfused (shunt), and"/>
 <result pre="also partly explain the efficacy of proning in patients with" exact="respiratory" post="failure [37]. Recent findings demonstrated that SARS-CoV-2 also infect"/>
 <result pre="cells, causing activation and secretion of inflammatory cytokines [38]. Direct" exact="infection" post="of lymphocytes via ACE2 binding had been previously demonstrated"/>
 <result pre="said that SARS-CoV could be considered halfway between a common" exact="respiratory" post="virus and a lymphotropic virus such as HIV [40]."/>
 <result pre="replicate in lymphocytes, and it is uncertain whether direct lymphocyte" exact="infection" post="can contribute to the lymphopenia associated with severe Covid-19."/>
 <result pre="is uncertain whether direct lymphocyte infection can contribute to the" exact="lymphopenia" post="associated with severe Covid-19. Indeed, lymphopenia may just be"/>
 <result pre="can contribute to the lymphopenia associated with severe Covid-19. Indeed," exact="lymphopenia" post="may just be due to apoptosis as a part"/>
 <result pre="of a multilinear cytopenia induced by hypercytokinemia or by overt" exact="hemophagocytic lymphohistiocytosis" post="[7,41]. 2.1.2. Innate Immune Response (Figure 1a II) The"/>
 <result pre="Immune Response (Figure 1a II) The initial response to coronaviruses" exact="infection" post="by the innate immune system plays a pivotal role"/>
 <result pre="in the pathway to an effective immune response leading to" exact="viral" post="clearance. Eukaryotic cells have several sensors, so-called pattern-recognition receptors"/>
 <result pre="compartment, Toll-like receptor 3 (TLR3) recognizes double-stranded RNA derived by" exact="viral" post="replication, while TLR7, TLR8, and TLR9 recognize respectively single-stranded"/>
 <result pre="the two RNA sensors Retinoic Acid-Inducible Gene I (RIG-I) and" exact="Melanoma" post="Differentiation-Associated protein 5 (MDA5) recognize double-stranded RNA intermediates produced"/>
 <result pre="Differentiation-Associated protein 5 (MDA5) recognize double-stranded RNA intermediates produced during" exact="viral" post="replication. Activation of cellular sensors elicits the production of"/>
 <result pre="viral replication. Activation of cellular sensors elicits the production of" exact="type I" post="IFNs and other inflammatory cytokines, which act on the"/>
 <result pre="response to interferon signaling [47]. Similarly, MERS CoV suppresses RIG-I-induced" exact="type I" post="and type III IFN production interfering with Tripartite Motif"/>
 <result pre="signaling [47]. Similarly, MERS CoV suppresses RIG-I-induced type I and" exact="type III" post="IFN production interfering with Tripartite Motif Containing 25 (TRIM25)-mediated"/>
 <result pre="that IFN-I production in the very early phase of the" exact="infection" post="is a crucial step affecting the course of the"/>
 <result pre="infection, the timing of the IFN-I response directly influences the" exact="disease" post="outcome, as early administration of IFN-I protects mice from"/>
 <result pre="while delayed treatment does not prevent the development of fatal" exact="pneumonia" post="and cytokine storm [49]. Thus, it is logical to"/>
 <result pre="assume that a properly functioning pathway from the sensing of" exact="viral" post="nucleic acids to IFN production is a prerequisite for"/>
 <result pre="proteins involved in the IFN cascade are associated with mendelian" exact="susceptibility to" post="severe viral infections [50]. The autocrine effects of IFN"/>
 <result pre="the IFN cascade are associated with mendelian susceptibility to severe" exact="viral" post="infections [50]. The autocrine effects of IFN include changes"/>
 <result pre="IFN cascade are associated with mendelian susceptibility to severe viral" exact="infections" post="[50]. The autocrine effects of IFN include changes of"/>
 <result pre="a set of antiviral genes, such as Interferon Induced Transmembrane" exact="Protein" post="3 (IFITM3) that reduce further cell infection by viral"/>
 <result pre="Interferon Induced Transmembrane Protein 3 (IFITM3) that reduce further cell" exact="infection" post="by viral particles [53]. Of note, IFITM3 mutations have"/>
 <result pre="Transmembrane Protein 3 (IFITM3) that reduce further cell infection by" exact="viral" post="particles [53]. Of note, IFITM3 mutations have been associated"/>
 <result pre="levels in blood from severe SARS-CoV or SARS-CoV-2 patients were" exact="lower" post="than normal, but this may not necessarily reflect a"/>
 <result pre="infection, DCs migrate to the draining lymph nodes, and present" exact="viral" post="antigens to virus-specific T cells triggering adaptive immune response"/>
 <result pre="to blood and spleen contributing to the spread of the" exact="infection" post="[63]. Liao et al., analyzing cells from bronchoalveolar lavage"/>
 <result pre="from bronchoalveolar lavage of patients with Covid-19, showed that severe" exact="disease" post="course was associated with a prevalence of monocyte-derived macrophages"/>
 <result pre="milder cases, tissue resident macrophages contributed to the expansion of" exact="clonal" post="CD8 T cells [64]. Interestingly, in a mouse model"/>
 <result pre="inflammatory macrophages protected the animals from lethal infection, without affecting" exact="viral" post="load [65], whereas removal of neutrophils led to no"/>
 <result pre="of neutrophils in a mouse model of severe influenza hindered" exact="viral" post="clearance. In this model, ablation of IL-6 accounted for"/>
 <result pre="the large majority of infected subjects can recover from the" exact="infection" post="owing to a balanced immune response. In Figure 1a,"/>
 <result pre="infection, based on analogies to what we learnt from other" exact="viral" post="infections. Recruitment of antiviral T cells is thought to"/>
 <result pre="occur mainly in draining peribronchial lymph nodes, where DCs bring" exact="viral" post="antigens. The process of recruitment and expansion of lymphocytes"/>
 <result pre="expansion of lymphocytes is likely to start some days after" exact="virus infection" post="and to take about a week in normal conditions."/>
 <result pre="of lymphocytes is likely to start some days after virus" exact="infection" post="and to take about a week in normal conditions."/>
 <result pre="conditions. A crucial aspect to contrast the spreading of the" exact="infection" post="is the availability of a large T cell repertoire,"/>
 <result pre="spreading is particularly important, as during the kinetics of the" exact="infection" post="the coronaviruses tend to dampen T-cell response by several"/>
 <result pre="effective response to novel viruses, for which there is no" exact="acquired" post="specific memory to be recalled [68]. Of note, in"/>
 <result pre="epitopes has been proposed as a strategy to fight emerging" exact="respiratory" post="coronaviruses. 2.1.7. Activation of CD8 Mediated Cytotoxicity and B"/>
 <result pre="strictly required to overcome the disease, since two subjects with" exact="congenital" post="agammaglobulinemia spontaneously recovered from Covid-19 pneumonia [71]. In contrast,"/>
 <result pre="required to overcome the disease, since two subjects with congenital" exact="agammaglobulinemia" post="spontaneously recovered from Covid-19 pneumonia [71]. In contrast, subjects"/>
 <result pre="since two subjects with congenital agammaglobulinemia spontaneously recovered from Covid-19" exact="pneumonia" post="[71]. In contrast, subjects with common variable immunodeficiency, who"/>
 <result pre="spontaneously recovered from Covid-19 pneumonia [71]. In contrast, subjects with" exact="common variable immunodeficiency," post="who have defective but not absent B-cell function, tend"/>
 <result pre="antiviral antibodies may also be produced, which could even enhance" exact="viral" post="entry in cells expressing the Fc receptor for immunoglobulins"/>
 <result pre="immunoglobulins [73]. This phenomenon, named ADE (antibody dependent enhancement of" exact="viral" post="entry) has been well described for other viruses and"/>
 <result pre="same family. For example, subjects who recovered from a first" exact="infection" post="with Dengue virus may get infected again with worse"/>
 <result pre="For example, subjects who recovered from a first infection with" exact="Dengue" post="virus may get infected again with worse course because"/>
 <result pre="presence of enhancing antibodies [75]. Similarly, subjects who recovered from" exact="Dengue" post="may undergo a severe course from Zika virus infection"/>
 <result pre="recovered from Dengue may undergo a severe course from Zika" exact="virus infection" post="and vice versa [76]. The occurrence of ADE has"/>
 <result pre="from Dengue may undergo a severe course from Zika virus" exact="infection" post="and vice versa [76]. The occurrence of ADE has"/>
 <result pre="Liu et al. showed in an animal model of SARS-CoV" exact="infection" post="that the presence of anti-spike IgG actually promoted proinflammatory"/>
 <result pre="recruitment and lung injury. Moreover, sera from SARS-deceased patients enhanced" exact="monocyte" post="chemoattractant protein 1 (MCP1) and IL-8 production by human"/>
 <result pre="vasculitis-related antibodies, e.g., antiphospholipid antibodies, may complicate and worsen the" exact="vascular" post="inflammation [79,80]. Interestingly, several clinical observations both with SARS-CoV"/>
 <result pre="interaction of S protein with ACE2 [83]. 2.1.9. Block of" exact="Viral" post="Spreading (Figure 1a IX) Altogether, NK cell and CD8"/>
 <result pre="of infected cells, clearance of virus inside macrophages, prevention of" exact="viral" post="spreading by antibodies, may contribute to the containment of"/>
 <result pre="infection. 2.1.10. Anti-Inflammatory Recovery (Figure 1a X) The recovery of" exact="viral" post="infections is associated with switch-off mechanisms, which include production"/>
 <result pre="2.1.10. Anti-Inflammatory Recovery (Figure 1a X) The recovery of viral" exact="infections" post="is associated with switch-off mechanisms, which include production of"/>
 <result pre="mechanisms, which include production of anti-inflammatory cytokines and apoptosis of" exact="infiltrating" post="immune cells [84]. 2.2. A Possible Scenario of Immune"/>
 <result pre="cells [84]. 2.2. A Possible Scenario of Immune Response in" exact="Severe" post="Covid-19 Hereafter, for explanatory purposes, we will consider the"/>
 <result pre="elderly subjects may fail recruiting enough virus-reactive lymphocytes to contrast" exact="infections" post="from viruses for which they do not have immunological"/>
 <result pre="courses of disease. Other factors affecting the course of the" exact="infection" post="may include the production of non-neutralizing antibodies enhancing viral"/>
 <result pre="the infection may include the production of non-neutralizing antibodies enhancing" exact="viral" post="spreading and entry into cells (by ADE mechanism), or"/>
 <result pre="entry into cells (by ADE mechanism), or the worsening of" exact="vascular" post="damage by autoantibodies. Impaired innate immunity, either due to"/>
 <result pre="been demonstrated, in fact, that blocking IFN-I signaling in MERS-CoV" exact="infection" post="impairs virus-specific T-cell responses, leading to increased inflammation and"/>
 <result pre="slow immune reaction may not be able to eradicate the" exact="infection" post="in subjects affected with various comorbidities that can reduce"/>
 <result pre="cytokines. Interestingly, depletion of lymphocytes and increase of neutrophils in" exact="peripheral" post="blood are changes typically associated with worsening of disease"/>
 <result pre="in peripheral blood are changes typically associated with worsening of" exact="disease" post="course. Although direct infection may account for increased lymphocyte"/>
 <result pre="changes typically associated with worsening of disease course. Although direct" exact="infection" post="may account for increased lymphocyte apoptosis, it seems more"/>
 <result pre="inflammatory cytokines, similarly to what has been described for other" exact="viral" post="illnesses, even if lymphopenia may also partly be due"/>
 <result pre="what has been described for other viral illnesses, even if" exact="lymphopenia" post="may also partly be due to accumulation of lymphocytes"/>
 <result pre="[86,87,88,89]. For example, a direct correlation between serum IFN-Î± and" exact="lymphocyte depletion" post="was described in pigs with swine flu [90] and"/>
 <result pre="serum IFN-Î± and lymphocyte depletion was described in pigs with" exact="swine flu" post="[90] and confirmed in experimental models of viral infection"/>
 <result pre="with swine flu [90] and confirmed in experimental models of" exact="viral infection" post="in mice lacking type I interferon receptor IFNAR [91]."/>
 <result pre="swine flu [90] and confirmed in experimental models of viral" exact="infection" post="in mice lacking type I interferon receptor IFNAR [91]."/>
 <result pre="confirmed in experimental models of viral infection in mice lacking" exact="type I" post="interferon receptor IFNAR [91]. Thus, the shortage of virus-specific"/>
 <result pre="response in a group of patients with severe Covid-19 with" exact="respiratory" post="failure highlighted features supportive of either lymphocyte depletion with"/>
 <result pre="severe Covid-19 with respiratory failure highlighted features supportive of either" exact="lymphocyte depletion" post="with low Human Leukocyte Antigen -DR (HLA-DR) expression on"/>
 <result pre="highlighted features supportive of either lymphocyte depletion with low Human" exact="Leukocyte" post="Antigen -DR (HLA-DR) expression on monocytes, or macrophage activation"/>
 <result pre="on monocytes, or macrophage activation syndrome. Subjects with macrophage activation" exact="syndrome" post="had higher serum C reactive protein (CRP), ferritin, and"/>
 <result pre="serum C reactive protein (CRP), ferritin, and IL-1Î² levels and" exact="lower" post="white blood cell count than those with lymphocyte depletion."/>
 <result pre="levels and lower white blood cell count than those with" exact="lymphocyte depletion." post="Conversely, subjects with lymphocyte depletion had higher levels of"/>
 <result pre="cell count than those with lymphocyte depletion. Conversely, subjects with" exact="lymphocyte depletion" post="had higher levels of IL-6 and a trend for"/>
 <result pre="a subset of severe cases has been shown an impaired" exact="type I" post="interferon activation, it might be possible that lymphopenia persistence"/>
 <result pre="impaired type I interferon activation, it might be possible that" exact="lymphopenia" post="persistence in this setting might be type I interferon"/>
 <result pre="be possible that lymphopenia persistence in this setting might be" exact="type I" post="interferon independent. On the contrary, increase of neutrophils is"/>
 <result pre="IL-1 targeted therapies and colchicine [94]. The vicious circle between" exact="vascular" post="damage, lung damage, inflammation, and immune paralysis can rapidly"/>
 <result pre="fatalities, especially when patients cannot endure the challenge of the" exact="infection" post="on vital functions, because of comorbidities (Figure 2). Acute"/>
 <result pre="the infection on vital functions, because of comorbidities (Figure 2)." exact="Acute respiratory distress syndrome" post="(ARDS) can result from alveolar cell damage and lung"/>
 <result pre="infection on vital functions, because of comorbidities (Figure 2). Acute" exact="respiratory" post="distress syndrome (ARDS) can result from alveolar cell damage"/>
 <result pre="vital functions, because of comorbidities (Figure 2). Acute respiratory distress" exact="syndrome" post="(ARDS) can result from alveolar cell damage and lung"/>
 <result pre="distress syndrome (ARDS) can result from alveolar cell damage and" exact="lung inflammation" post="and can be worsened by ACE2 depletion, lung vasculopathy"/>
 <result pre="by ACE2 depletion, lung vasculopathy with micro-thrombosis [95]. The diseased" exact="respiratory" post="environment is also exposed to the risk from secondary"/>
 <result pre="diseased respiratory environment is also exposed to the risk from" exact="secondary" post="bacterial or fungal infections, which can precipitate a fatal"/>
 <result pre="respiratory environment is also exposed to the risk from secondary" exact="bacterial" post="or fungal infections, which can precipitate a fatal course"/>
 <result pre="fungal infections, which can precipitate a fatal course of the" exact="infection" post="[7]. Heart or kidney failure can also occur in"/>
 <result pre="which can precipitate a fatal course of the infection [7]." exact="Heart" post="or kidney failure can also occur in severe cases"/>
 <result pre="precipitate a fatal course of the infection [7]. Heart or" exact="kidney failure" post="can also occur in severe cases [96]. A crucial"/>
 <result pre="occur in severe cases [96]. A crucial aspect of the" exact="disease" post="is coagulopathy that can accelerate the progression toward multiorgan"/>
 <result pre="severe cases [96]. A crucial aspect of the disease is" exact="coagulopathy" post="that can accelerate the progression toward multiorgan failure [97]."/>
 <result pre="can accelerate the progression toward multiorgan failure [97]. Vasculopathy and" exact="coagulopathy" post="are probably related to the infection of endothelial cells"/>
 <result pre="failure [97]. Vasculopathy and coagulopathy are probably related to the" exact="infection" post="of endothelial cells by SARS-CoV-2 [31,98], but it could"/>
 <result pre="of complement [79,80,99]. 3. Immunity to SARS-CoV-2 and Factors Determining" exact="Disease" post="Progression There are probably distinct factors affecting the disease"/>
 <result pre="Determining Disease Progression There are probably distinct factors affecting the" exact="disease" post="progression in Covid-19. The stronger risk factor lies in"/>
 <result pre="greater detail. 3.1. The Age Gradient The risk of severe" exact="disease" post="and death in Covid-19 increase directly with age. This"/>
 <result pre="knowledge, children infected with SARS-CoV-2 are less likely to be" exact="symptomatic" post="or develop severe symptoms [21,100]. Reasons for this difference"/>
 <result pre="related to age-dependent immune factors as well as dynamics of" exact="viral" post="exposure [21]. 3.1.1. ACE2 Density and Distribution Changes with"/>
 <result pre="why young people seem to be less susceptible to severe" exact="infections" post="from SARS-CoV-2 [101]. Besides age, several other factors also"/>
 <result pre="upregulates the expression of ACE2; this may account for a" exact="lower" post="than expected prevalence of smokers in diseases cohorts, even"/>
 <result pre="Those observations were used to speculate on a possible increased" exact="susceptibility to" post="SARS-CoV-2 infection in patients under those treatments, or vice"/>
 <result pre="used to speculate on a possible increased susceptibility to SARS-CoV-2" exact="infection" post="in patients under those treatments, or vice versa, if"/>
 <result pre="[104] and an electronic medical record analysis [105]) including a" exact="total" post="of more than 21,000 infected patients failed to identify"/>
 <result pre="identify any correlation between ACE inhibitor or ARBs treatment and" exact="infection" post="risk or disease severity. Scientific societies advice not to"/>
 <result pre="between ACE inhibitor or ARBs treatment and infection risk or" exact="disease" post="severity. Scientific societies advice not to discontinue such therapies"/>
 <result pre="explain why older people are more prone to develop severe" exact="disease" post="during viral infections. This is particularly true for newly"/>
 <result pre="older people are more prone to develop severe disease during" exact="viral" post="infections. This is particularly true for newly arising infectious"/>
 <result pre="during viral infections. This is particularly true for newly arising" exact="infectious" post="organisms, for which there is no protection from pre-existing"/>
 <result pre="Studies in animal models showed a decline in reactivity to" exact="viral" post="epitopes with a low naive precursor frequency in aged"/>
 <result pre="development of adaptive immunity leading to an unremitting cycle of" exact="viral" post="replication and innate cytokine-chemokine release [108]. Coherently, a relatively"/>
 <result pre="lymphocyte repertoire in children and immune memory for past cross-reacting" exact="viral" post="strains in old people. Interestingly, the repertoire of naive"/>
 <result pre="be reduced by the involvement of adaptive immune system in" exact="recurrent" post="infections [109]. Whether immunosenescence associated with aging, and specifically"/>
 <result pre="reduced by the involvement of adaptive immune system in recurrent" exact="infections" post="[109]. Whether immunosenescence associated with aging, and specifically T"/>
 <result pre="of old people to SARS is still uncertain [21]. 3.1.3." exact="Age-Related" post="Changes in Antibody Production Deterioration of immune response in"/>
 <result pre="to SARS is still uncertain [21]. 3.1.3. Age-Related Changes in" exact="Antibody" post="Production Deterioration of immune response in elderly represents a"/>
 <result pre="they can do harm by enhancing inflammatory immune responses and" exact="viral" post="entry into cells [113,114]. However, even antibodies mediating viral"/>
 <result pre="and viral entry into cells [113,114]. However, even antibodies mediating" exact="viral infection" post="can be protective in certain circumstances [115]. Even if"/>
 <result pre="viral entry into cells [113,114]. However, even antibodies mediating viral" exact="infection" post="can be protective in certain circumstances [115]. Even if"/>
 <result pre="dysregulation of IFN pathways could contribute to lethality from SARS-CoV-2" exact="infection" post="by determining the inability to control viral replication at"/>
 <result pre="lethality from SARS-CoV-2 infection by determining the inability to control" exact="viral" post="replication at the beginning of the infection, and later"/>
 <result pre="3.2. Why Do Some Young People Become Critically Ill? 3.2.1." exact="Viral" post="Load In experimental conditions, the inoculum dose is a"/>
 <result pre="dose is a crucial factor influencing the outcome of the" exact="infection" post="from many viruses. High inoculum dose of viruses with"/>
 <result pre="adaptive immune response develops, especially with fast-replicating viruses. In influenza" exact="virus infection," post="cytotoxic CD8 cells are the main player in killing"/>
 <result pre="the main player in killing virus-infected cells. However, with high" exact="viral" post="inoculum dose cytotoxic CD8 cells can be killed by"/>
 <result pre="an in vitro model to examine the effects of influenza" exact="infection" post="on DC function, T-cell proliferation occurred at low multiplicities"/>
 <result pre="IFN response, as mentioned before, have been found to confer" exact="susceptibility to" post="a narrow range of virus infections or even one"/>
 <result pre="found to confer susceptibility to a narrow range of virus" exact="infections" post="or even one particular virus. Such an example is"/>
 <result pre="the TLR3 signaling pathway which predisposes to severe presentation of" exact="herpes" post="simplex virus (HSV), including HSV encephalitis [50]. Whether patients"/>
 <result pre="to severe presentation of herpes simplex virus (HSV), including HSV" exact="encephalitis" post="[50]. Whether patients who develop lethal Covid-19 infections harbor"/>
 <result pre="including HSV encephalitis [50]. Whether patients who develop lethal Covid-19" exact="infections" post="harbor genetic variants predisposing to disease progression is unknown."/>
 <result pre="who develop lethal Covid-19 infections harbor genetic variants predisposing to" exact="disease" post="progression is unknown. However, this hypothesis is being investigated"/>
 <result pre="Affecting T Cell Repertoire It is well-known that subjects with" exact="combined immunodeficiencies" post="(CID) are susceptible to severe illnesses from various viruses"/>
 <result pre="are susceptible to severe illnesses from various viruses [50]. Accordingly," exact="primary" post="immunodeficiencies might explain a proportion of the rare Covid-19"/>
 <result pre="with these disorders can encounter SARS-CoV-2 and develop a severe" exact="disease" post="course. Indeed, the only records of CIDs detected after"/>
 <result pre="course. Indeed, the only records of CIDs detected after severe" exact="viral" post="illness concern subjects with undiagnosed idiopathic CD4 T-cell lymphopenia"/>
 <result pre="severe viral illness concern subjects with undiagnosed idiopathic CD4 T-cell" exact="lymphopenia" post="who developed severe varicella [120] or subjects with Cartilage"/>
 <result pre="T-cell lymphopenia who developed severe varicella [120] or subjects with" exact="Cartilage Hair Hypoplasia" post="[121]. Covid-19 could also have a worse course in"/>
 <result pre="highly active antiretroviral therapy [122]. 3.2.4. Immunodeficiencies Affecting Cytotoxic Functions" exact="Severe" post="cases of Covid-19 have been associated with the development"/>
 <result pre="cases of Covid-19 have been associated with the development of" exact="secondary" post="hemophagocytic lymphohistiocytosis (sHLH). Inborn errors of immunity affecting NK"/>
 <result pre="of Covid-19 have been associated with the development of secondary" exact="hemophagocytic lymphohistiocytosis" post="(sHLH). Inborn errors of immunity affecting NK and CD8"/>
 <result pre="and CD8 T-mediated cytotoxicity have been associated with unexpected fatal" exact="infection" post="from various viruses, presenting with the clinical picture of"/>
 <result pre="infection from various viruses, presenting with the clinical picture of" exact="primary" post="HLH [123]. Thus, it is possible that some patients"/>
 <result pre="to explain a significant proportion of severe cases. Patients with" exact="rheumatic" post="conditions such as systemic juvenile idiopathic arthritis and systemic"/>
 <result pre="proportion of severe cases. Patients with rheumatic conditions such as" exact="systemic" post="juvenile idiopathic arthritis and systemic lupus erythematosus who develop"/>
 <result pre="of severe cases. Patients with rheumatic conditions such as systemic" exact="juvenile idiopathic arthritis" post="and systemic lupus erythematosus who develop sHLH-like inflammatory complications"/>
 <result pre="cases. Patients with rheumatic conditions such as systemic juvenile idiopathic" exact="arthritis" post="and systemic lupus erythematosus who develop sHLH-like inflammatory complications"/>
 <result pre="with rheumatic conditions such as systemic juvenile idiopathic arthritis and" exact="systemic" post="lupus erythematosus who develop sHLH-like inflammatory complications (named macrophage"/>
 <result pre="rheumatic conditions such as systemic juvenile idiopathic arthritis and systemic" exact="lupus erythematosus" post="who develop sHLH-like inflammatory complications (named macrophage activation syndrome)"/>
 <result pre="case fatality from SARS-Cov-2 has been attributed to a monogenic" exact="primary" post="immunodeficiency. 3.2.5. HLA Haplotypes Correlations Bioinformatic tools have already"/>
 <result pre="provide information to identify subjects with increased risk of severe" exact="disease" post="and guide social interventions. For example, HLA-B*46:01 haplotype has"/>
 <result pre="by different coronavirus, thus representing a possible protective factor for" exact="disease" post="severity through cross-response. To identify high risk populations is"/>
 <result pre="of key relevance to implement stratified social distancing rules and" exact="disease" post="prevention (i.e., vaccine administration) priorities. To date, there are"/>
 <result pre="from bats, likely mediated by some other animal species as" exact="intermediate" post="host [127]. Bats are known to be asymptomatic reservoirs"/>
 <result pre="be asymptomatic reservoirs for many different viruses that cause serious" exact="disease" post="in humans and non-human primates such as SARS and"/>
 <result pre="can bats coexist with so many viruses with no overt" exact="disease" post="could provide guidance for the identification of treatment targets"/>
 <result pre="immune system coevolved with viruses mitigating cellular pathways activated by" exact="viral infection" post="to reach a state of reciprocal tolerance. Bats may"/>
 <result pre="system coevolved with viruses mitigating cellular pathways activated by viral" exact="infection" post="to reach a state of reciprocal tolerance. Bats may"/>
 <result pre="a result of these unique adaptations at the cost of" exact="infection" post="persistence and prolonged viral shedding [132], which is probably"/>
 <result pre="unique adaptations at the cost of infection persistence and prolonged" exact="viral" post="shedding [132], which is probably a prerequisite for viral"/>
 <result pre="prolonged viral shedding [132], which is probably a prerequisite for" exact="viral" post="spillover to other species. Bat cells are capable of"/>
 <result pre="propagation by inducing an effective IFN production in response to" exact="viral" post="RNA, while limiting the expression of virus-induced inflammatory cytokines."/>
 <result pre="is an important sensor for cellular stresses as well as" exact="viral" post="and bacterial infections. NLRP3 regulates the secretion of proinflammatory"/>
 <result pre="important sensor for cellular stresses as well as viral and" exact="bacterial infections." post="NLRP3 regulates the secretion of proinflammatory cytokines interleukin 1"/>
 <result pre="Critical Mechanisms of Potential Relevance to Determine the Course of" exact="Infection" post="and Possible Targets of Therapies A good balance between"/>
 <result pre="recruitment and expansion of virus-specific lymphocytes can lead to early" exact="viral" post="clearance, preventing the development of significant organ damage. Conversely,"/>
 <result pre="Conversely, slower activation of specific immunity may result in undisturbed" exact="viral" post="replication, with widespread cell damage and secondary inflammatory amplification."/>
 <result pre="result in undisturbed viral replication, with widespread cell damage and" exact="secondary" post="inflammatory amplification. Notably, SARS-CoV2 is a fast-replicating virus, reaching"/>
 <result pre="secondary inflammatory amplification. Notably, SARS-CoV2 is a fast-replicating virus, reaching" exact="viral" post="load peak in the upper airways within 5â€&quot;6 days"/>
 <result pre="is a fast-replicating virus, reaching viral load peak in the" exact="upper" post="airways within 5â€&quot;6 days from symptoms onset, thus significantly"/>
 <result pre="a prompt and adequate immune response is crucial to avoid" exact="infection" post="progression [140,141]. All the components of immunity may act"/>
 <result pre="foe: IFNs are necessary in the first phase of the" exact="infection" post="but may become harmful afterwards; tissue macrophages and DCs"/>
 <result pre="bringing the virus to other organs; neutrophils are needed for" exact="viral" post="clearance in animal models of infection with influenza virus,"/>
 <result pre="neutrophils are needed for viral clearance in animal models of" exact="infection" post="with influenza virus, but are primary players of tissue"/>
 <result pre="in animal models of infection with influenza virus, but are" exact="primary" post="players of tissue damage in Covid-19; antibodies may be"/>
 <result pre="in Covid-19; antibodies may be protective or harmful by enhancing" exact="viral" post="entry or by targeting vascular structures. Healthy people may"/>
 <result pre="protective or harmful by enhancing viral entry or by targeting" exact="vascular" post="structures. Healthy people may cope with an imbalance in"/>
 <result pre="rate because of the establishment of vicious circles between inflammatory," exact="respiratory" post="and vascular processes. A possible list of critical mechanisms"/>
 <result pre="of the establishment of vicious circles between inflammatory, respiratory and" exact="vascular" post="processes. A possible list of critical mechanisms affecting the"/>
 <result pre="1. 6. Therapies under Evaluation Supportive care and prevention of" exact="bacterial" post="superinfection are the mainstay of management in patients with"/>
 <result pre="evaluation in clinical trials. 6.1. Antivirals Antivirals aim at blocking" exact="viral" post="replication and related cell damage. Even though antivirals seem"/>
 <result pre="be the most obvious causative therapy, their efficacy might be" exact="limited" post="to the initial phase of the illness and might"/>
 <result pre="randomized trial in Covid-19 was open-label and included 199 hospitalized" exact="adult" post="patients with confirmed SARS-CoV-2 infection. No adjunctive benefit in"/>
 <result pre="time to clinical improvement, mortality rates at 28 days and" exact="viral" post="RNA load at various time point was observed in"/>
 <result pre="100) [143]. Remdesivir is a nucleotide analogue prodrug that inhibits" exact="viral" post="RNA polymerases. In vitro testing of remdesivir has shown"/>
 <result pre="virus. Favipiravir is a nucleotide prodrug whose active compound inhibits" exact="viral" post="RNA-dependent RNA polymerase. Favipiravir is approved for the treatment"/>
 <result pre="polymerase. Favipiravir is approved for the treatment of influenza virus" exact="infections" post="in Japan and China. The results of a small"/>
 <result pre="(n = 45). Patients in the favipiravir group had faster" exact="viral" post="clearance (4 days vs. 11 days) and more frequent"/>
 <result pre="its efficacy [149]. Ribavirin is a nucleoside analogue that inhibits" exact="viral" post="RNA-dependent RNA polymerase with in vitro activity against SARS-CoV"/>
 <result pre="and 4 reported possible harm due to the occurrence of" exact="hemolytic anemia" post="and liver toxicity in a high proportion of treated"/>
 <result pre="4 reported possible harm due to the occurrence of hemolytic" exact="anemia" post="and liver toxicity in a high proportion of treated"/>
 <result pre="of treated patients [150]. With these premises ribavirin likely has" exact="limited" post="value for the treatment of Covid-19. 6.2. Chloroquine and"/>
 <result pre="in vitro SARS-CoV-2 [151]. These agents appear to interfere with" exact="viral" post="entry into cells as well as viral replication. In"/>
 <result pre="to interfere with viral entry into cells as well as" exact="viral" post="replication. In addition, they attenuate cytokine production and inhibit"/>
 <result pre="[151]. Given the long history of use in patients with" exact="malaria" post="as well as in patients with rheumatologic conditions, and"/>
 <result pre="for the treatment of Covid-19 has widely spread despite very" exact="limited" post="efficacy data and emerging concerns of cardiotoxicity, especially for"/>
 <result pre="center open label study on 36 patients with Covid-19. The" exact="primary" post="outcome in the trial was viral clearance from the"/>
 <result pre="patients with Covid-19. The primary outcome in the trial was" exact="viral" post="clearance from the nasopharynx, not a clinical outcome. At"/>
 <result pre="70% of patients who received hydroxychloroquine (n = 20) achieved" exact="viral" post="clearance compared to 12.5% of patients in the control"/>
 <result pre="of azithromycin since all the patients receiving the combination achieved" exact="viral" post="clearance (n = 6). Following the publication, attention was"/>
 <result pre="Agents Significantly increased amounts of several proinflammatory cytokines driving the" exact="uncontrolled" post="immune inflammatory response of Covid-19 have been measured in"/>
 <result pre="measured in serum of patients who develop severe or fatal" exact="disease" post="[158]. Which mediators have the most important role in"/>
 <result pre="antibody targeting IL-6 receptor, approved for the treatment of cytokine-release" exact="syndrome" post="following chimeric antigen receptor T-cell (CAR-T) therapy [159]. In"/>
 <result pre="Covid-19 was associated with rapid cessation of fever, improvement of" exact="respiratory" post="functions and thoracic imaging, as well as reduction of"/>
 <result pre="case series on 100 patients admitted to hospital for Covid-19" exact="pneumonia" post="showed an improved or stable respiratory status in 77"/>
 <result pre="admitted to hospital for Covid-19 pneumonia showed an improved or" exact="stable" post="respiratory status in 77 patients within 10 days from"/>
 <result pre="to hospital for Covid-19 pneumonia showed an improved or stable" exact="respiratory" post="status in 77 patients within 10 days from treatment"/>
 <result pre="data on compassionate use of siltuximab in 21 patients with" exact="pneumonia" post="have shown improvement in 7, yet no conclusions can"/>
 <result pre="possibility that its inhibition can result in greater incidence of" exact="opportunistic infections" post="in treated patients, especially when given together with corticosteroids."/>
 <result pre="that its inhibition can result in greater incidence of opportunistic" exact="infections" post="in treated patients, especially when given together with corticosteroids."/>
 <result pre="high doses of anakinra intravenously in 29 patients with severe" exact="disease" post="[164], with rapid decrease of inflammatory markers, progressive amelioration"/>
 <result pre="[164], with rapid decrease of inflammatory markers, progressive amelioration of" exact="respiratory" post="function and increased survival compared to a retrospective cohort,"/>
 <result pre="emapalumab, an anti-IFN-Î³ monoclonal antibody used for the treatment of" exact="hemophagocytic lymphohistiocytosis," post="has been proposed [167]. Both drugs are under evaluation"/>
 <result pre="in preclinical model that anti-TNFs ameliorate the course of severe" exact="respiratory" post="syncytial virus (RSV) and influenza in mice [170]. Notably,"/>
 <result pre="Intravenous Immunoglobulins (IVIG) Convalescent plasma has been used for various" exact="viral" post="infections including H1N1 influenza, SARS, and MERS with some"/>
 <result pre="Immunoglobulins (IVIG) Convalescent plasma has been used for various viral" exact="infections" post="including H1N1 influenza, SARS, and MERS with some evidence"/>
 <result pre="used in adults and children to prevent or to treat" exact="viral" post="infections such as cytomegalovirus, varicella zoster, and respiratory syncytial"/>
 <result pre="in adults and children to prevent or to treat viral" exact="infections" post="such as cytomegalovirus, varicella zoster, and respiratory syncytial virus."/>
 <result pre="to treat viral infections such as cytomegalovirus, varicella zoster, and" exact="respiratory" post="syncytial virus. Plasma from individuals who have recovered from"/>
 <result pre="Their role is unclear, nevertheless IVIG may have both a" exact="partial" post="inhibitory viral effect due to nonspecific cross-reaction, and a"/>
 <result pre="is unclear, nevertheless IVIG may have both a partial inhibitory" exact="viral" post="effect due to nonspecific cross-reaction, and a well-known immunomodulatory"/>
 <result pre="well-known immunomodulatory effect in several inflammatory conditions, including macrophage activation" exact="syndrome" post="[178]. IVIG use may be most relevant in patients"/>
 <result pre="most relevant in patients with specific organ involvement such as" exact="myocarditis" post="and Guillan-BarrÃ© syndrome, which have also been reported in"/>
 <result pre="which have also been reported in association with SARS CoV-2" exact="infection" post="[179]. 6.6. Interferons and JAK-Inhibitors Interferons are key molecules"/>
 <result pre="and ribavirin failed to show any improvement in mortality or" exact="viral" post="clearance [150,180]. Given the previously discussed role of IFN"/>
 <result pre="factor. In mouse models, IFN-I administration within 1 day after" exact="infection" post="protected mice from lethal MERS infection, while delayed treatment"/>
 <result pre="cells [181]. However, these drugs may also result in substantial" exact="depression" post="of the immune response. A small, non-randomized study reported"/>
 <result pre="reported a cohort of 12 patients hospitalized for moderate Covid-19" exact="pneumonia" post="who were treated with baricitinib in addition to lopinavir/ritonavir."/>
 <result pre="baricitinib-treated patients had a faster improvement of clinical conditions and" exact="respiratory" post="parameters, did not require intensive care, and were discharged"/>
 <result pre="tolerated in all patients, with no serious adverse events or" exact="opportunistic infections" post="[182]. Larger clinical trials are ongoing. 6.7. Corticosteroids Corticosteroids"/>
 <result pre="in all patients, with no serious adverse events or opportunistic" exact="infections" post="[182]. Larger clinical trials are ongoing. 6.7. Corticosteroids Corticosteroids"/>
 <result pre="lung injury. However, considerations have been made that beside suppressing" exact="lung inflammation," post="corticosteroids also inhibit immune responses and pathogen clearance. Observational"/>
 <result pre="but no clear association with improved survival, while demonstrating delayed" exact="viral" post="clearance and high rates of complications [150,183,184,185,186]. In a"/>
 <result pre="role of corticosteroids as adjunctive therapy in patients with severe" exact="pneumonia" post="caused by influenza, corticosteroid therapy seemed to confer an"/>
 <result pre="influenza, corticosteroid therapy seemed to confer an increased risk of" exact="secondary" post="bacterial infection and mortality [187]. It is noteworthy to"/>
 <result pre="corticosteroid therapy seemed to confer an increased risk of secondary" exact="bacterial infection" post="and mortality [187]. It is noteworthy to report, however,"/>
 <result pre="therapy seemed to confer an increased risk of secondary bacterial" exact="infection" post="and mortality [187]. It is noteworthy to report, however,"/>
 <result pre="series found that patients with ARDS treated with methylprednisolone exhibited" exact="lower" post="mortality (46% vs. 62%, hazard ratio for death 0.38,"/>
 <result pre="basis, taking into account factors as pre-existing medical conditions requiring" exact="chronic" post="corticosteroid use, or hemodynamic status [189]. 6.8. Other Therapeutic"/>
 <result pre="hemodynamic status [189]. 6.8. Other Therapeutic Strategies The observation that" exact="viral" post="entry into cells via ACE2 receptor requires priming by"/>
 <result pre="prompted in vitro trials with two clinically approved drugs for" exact="acute" post="pancreatitis (nafamostat and camostat) which resulted in blockade of"/>
 <result pre="in vitro trials with two clinically approved drugs for acute" exact="pancreatitis" post="(nafamostat and camostat) which resulted in blockade of viral"/>
 <result pre="acute pancreatitis (nafamostat and camostat) which resulted in blockade of" exact="viral" post="entry [16]. Another drug inhibiting TMPRSS2 is bromhexine, a"/>
 <result pre="widely used antitussive agent. Considering the role of TMPRSS2 in" exact="viral" post="entry, these drugs could be suitable as prophylaxis in"/>
 <result pre="currently undergoing clinical trials. The use of heparin for Covid-19-associated" exact="coagulopathy" post="and its adjunctive potential anti-inflammatory role has been previously"/>
 <result pre="adjunctive potential anti-inflammatory role has been previously discussed [190]. 7." exact="Acquired" post="Protection and Development of Vaccines It is too early"/>
 <result pre="be re-infected by SARS-CoV-2 after recovery from Covid-19. Re-detection of" exact="viral" post="RNA on nasopharyngeal swabs after two consecutive negative results"/>
 <result pre="in asymptomatic patients during the convalescent phase [191]. However, since" exact="viral" post="RNA shedding has been observed for days to weeks"/>
 <result pre="re-detected had a false negative result due to an insufficient" exact="viral" post="load of the specimen, or persistence of viral nucleic"/>
 <result pre="an insufficient viral load of the specimen, or persistence of" exact="viral" post="nucleic acids in the airways in the absence of"/>
 <result pre="persistence of viral nucleic acids in the airways in the" exact="absence of" post="the full, potentially infectious virus. Much of our understanding"/>
 <result pre="in the airways in the absence of the full, potentially" exact="infectious" post="virus. Much of our understanding of the immune response"/>
 <result pre="low or absent neutralizing antibodies [9]. The reasons why coronavirus" exact="infections" post="do not elicit robust and long-lasting antibody response are"/>
 <result pre="more important than the humoral response, both for recovering from" exact="primary" post="infection and to prevent reinfections. Unlike antibodies, SARS-CoV-specific memory,"/>
 <result pre="important than the humoral response, both for recovering from primary" exact="infection" post="and to prevent reinfections. Unlike antibodies, SARS-CoV-specific memory, CD8"/>
 <result pre="Virus-specific CD8 T cells are required for pathogen clearance during" exact="acute" post="infection. After that, memory CD8 T cells persist at"/>
 <result pre="enhancement of SARS-CoV specific CD8 T cells by immunization with" exact="viral" post="peptide-pulsed DCs results in a robust T-cell response, earlier"/>
 <result pre="Recent observation in agammaglobulinemic patients of spontaneous recovery from SARS-CoV-2" exact="infection" post="supports the hypothesis that T-cell immunity might be more"/>
 <result pre="humoral immunity being relevant especially in the first phase of" exact="virus infection," post="reducing the initial viral load and controlling its spreading"/>
 <result pre="in the first phase of virus infection, reducing the initial" exact="viral" post="load and controlling its spreading in respiratory organs, while"/>
 <result pre="reducing the initial viral load and controlling its spreading in" exact="respiratory" post="organs, while cellular immunity being important in the control"/>
 <result pre="authors declare no conflict of interest. References References 1.collab: WHOCoronavirus" exact="Disease" post="(COVID-19) DashboardAvailable online: https://www.covid19.who.int/2020(accessed on 5 May 2020) 2.ZhangS.DiaoM.YuW.PeiL.LinZ.ChenD.Estimation"/>
 <result pre="analysisInt. J. Infect. Dis.20209320120410.1016/j.ijid.2020.02.03332097725 3.SancheS.LinY.T.XuC.Romero-SeversonE.HengartnerN.KeR.High Contagiousness and Rapid Spread of" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2Emerg. Infect. Dis.20202610.3201/eid2607.200282 4.VerityR.OkellL.C.DorigattiI.WinskillP.WhittakerC.ImaiN.Cuomo-DannenburgG.ThompsonH.WalkerP.G.T.FuH.et al.Estimates"/>
 <result pre="J. Infect. Dis.20209320120410.1016/j.ijid.2020.02.03332097725 3.SancheS.LinY.T.XuC.Romero-SeversonE.HengartnerN.KeR.High Contagiousness and Rapid Spread of Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2Emerg. Infect. Dis.20202610.3201/eid2607.200282 4.VerityR.OkellL.C.DorigattiI.WinskillP.WhittakerC.ImaiN.Cuomo-DannenburgG.ThompsonH.WalkerP.G.T.FuH.et al.Estimates of"/>
 <result pre="Infect. Dis.20209320120410.1016/j.ijid.2020.02.03332097725 3.SancheS.LinY.T.XuC.Romero-SeversonE.HengartnerN.KeR.High Contagiousness and Rapid Spread of Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2Emerg. Infect. Dis.20202610.3201/eid2607.200282 4.VerityR.OkellL.C.DorigattiI.WinskillP.WhittakerC.ImaiN.Cuomo-DannenburgG.ThompsonH.WalkerP.G.T.FuH.et al.Estimates of the"/>
 <result pre="Dis.20209320120410.1016/j.ijid.2020.02.03332097725 3.SancheS.LinY.T.XuC.Romero-SeversonE.HengartnerN.KeR.High Contagiousness and Rapid Spread of Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2Emerg. Infect. Dis.20202610.3201/eid2607.200282 4.VerityR.OkellL.C.DorigattiI.WinskillP.WhittakerC.ImaiN.Cuomo-DannenburgG.ThompsonH.WalkerP.G.T.FuH.et al.Estimates of the severity"/>
 <result pre="2Emerg. Infect. Dis.20202610.3201/eid2607.200282 4.VerityR.OkellL.C.DorigattiI.WinskillP.WhittakerC.ImaiN.Cuomo-DannenburgG.ThompsonH.WalkerP.G.T.FuH.et al.Estimates of the severity of coronavirus" exact="disease" post="2019: A model-based analysisLancet Infect. Dis.202010.1016/S1473-3099(20)30243-7 5.McCombsA.KadelkaC.A model-based evaluation"/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: A descriptive studyLancet202039550751310.1016/S0140-6736(20)30211-732007143 8.ZhouF.YuT.DuR.FanG.LiuY.LiuZ.XiangJ.WangY.SongB.GuX.et al.Clinical course"/>
 <result pre="studyLancet202039550751310.1016/S0140-6736(20)30211-732007143 8.ZhouF.YuT.DuR.FanG.LiuY.LiuZ.XiangJ.WangY.SongB.GuX.et al.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: A retrospective cohort"/>
 <result pre="al.Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus" exact="Disease" post="2019â€&quot;COVID-NET, 14 States, March 1â€&quot;30, 2020MMWR Morb. Mortal Wkly."/>
 <result pre="Mortal Wkly. Rep.20206945846410.15585/mmwr.mm6915e332298251 11.WuF.ZhaoS.YuB.ChenY.M.WangW.SongZ.G.HuY.TaoZ.W.TianJ.H.PeiY.Y.et al.A new coronavirus associated with human" exact="respiratory" post="disease in ChinaNature202057926526910.1038/s41586-020-2008-332015508 12.TangX.WuC.LiX.SongY.YaoX.WuX.DuanY.ZhangH.WangY.QianZ.et al.On the origin and continuing"/>
 <result pre="Wkly. Rep.20206945846410.15585/mmwr.mm6915e332298251 11.WuF.ZhaoS.YuB.ChenY.M.WangW.SongZ.G.HuY.TaoZ.W.TianJ.H.PeiY.Y.et al.A new coronavirus associated with human respiratory" exact="disease" post="in ChinaNature202057926526910.1038/s41586-020-2008-332015508 12.TangX.WuC.LiX.SongY.YaoX.WuX.DuanY.ZhangH.WangY.QianZ.et al.On the origin and continuing evolution"/>
 <result pre="the Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long" exact="Structural" post="Studies of SARS CoronavirusJ. Virol.2020941710.1128/JVI.00127-2031996437 16.HoffmannM.Kleine-WeberH.SchroederS.KrugerN.HerrlerT.ErichsenS.SchiergensT.S.HerrlerG.WuN.H.NitscheA.et al.SARS-CoV-2 Cell Entry"/>
 <result pre="a Clinically Proven Protease InhibitorCell202018127128010.1016/j.cell.2020.02.05232142651 17.JiaH.P.LookD.C.ShiL.HickeyM.PeweL.NetlandJ.FarzanM.Wohlford-LenaneC.PerlmanS.McCrayP.B.Jr.ACE2 receptor expression and severe" exact="acute" post="respiratory syndrome coronavirus infection depend on differentiation of human"/>
 <result pre="Clinically Proven Protease InhibitorCell202018127128010.1016/j.cell.2020.02.05232142651 17.JiaH.P.LookD.C.ShiL.HickeyM.PeweL.NetlandJ.FarzanM.Wohlford-LenaneC.PerlmanS.McCrayP.B.Jr.ACE2 receptor expression and severe acute" exact="respiratory" post="syndrome coronavirus infection depend on differentiation of human airway"/>
 <result pre="Proven Protease InhibitorCell202018127128010.1016/j.cell.2020.02.05232142651 17.JiaH.P.LookD.C.ShiL.HickeyM.PeweL.NetlandJ.FarzanM.Wohlford-LenaneC.PerlmanS.McCrayP.B.Jr.ACE2 receptor expression and severe acute respiratory" exact="syndrome" post="coronavirus infection depend on differentiation of human airway epitheliaJ."/>
 <result pre="InhibitorCell202018127128010.1016/j.cell.2020.02.05232142651 17.JiaH.P.LookD.C.ShiL.HickeyM.PeweL.NetlandJ.FarzanM.Wohlford-LenaneC.PerlmanS.McCrayP.B.Jr.ACE2 receptor expression and severe acute respiratory syndrome coronavirus" exact="infection" post="depend on differentiation of human airway epitheliaJ. Virol.200579146141462110.1128/JVI.79.23.14614-14621.200516282461 18.WrappD.WangN.CorbettK.S.GoldsmithJ.A.HsiehC.L.AbionaO.GrahamB.S.McLellanJ.S.Cryo-EM"/>
 <result pre="protease TMPRSS2 activates a proteolytic cascade involving components of the" exact="tumor" post="microenvironment and promotes prostate cancer metastasisCancer Discov.201441310132510.1158/2159-8290.CD-13-101025122198 23.GudbjartssonD.F.HelgasonA.JonssonH.MagnussonO.T.MelstedP.NorddahlG.L.SaemundsdottirJ.SigurdssonA.SulemP.AgustsdottirA.B.et al.Spread"/>
 <result pre="proteolytic cascade involving components of the tumor microenvironment and promotes" exact="prostate cancer" post="metastasisCancer Discov.201441310132510.1158/2159-8290.CD-13-101025122198 23.GudbjartssonD.F.HelgasonA.JonssonH.MagnussonO.T.MelstedP.NorddahlG.L.SaemundsdottirJ.SigurdssonA.SulemP.AgustsdottirA.B.et al.Spread of SARS-CoV-2 in the Icelandic"/>
 <result pre="cascade involving components of the tumor microenvironment and promotes prostate" exact="cancer" post="metastasisCancer Discov.201441310132510.1158/2159-8290.CD-13-101025122198 23.GudbjartssonD.F.HelgasonA.JonssonH.MagnussonO.T.MelstedP.NorddahlG.L.SaemundsdottirJ.SigurdssonA.SulemP.AgustsdottirA.B.et al.Spread of SARS-CoV-2 in the Icelandic"/>
 <result pre="al.Differential downregulation of ACE2 by the spike proteins of severe" exact="acute" post="respiratory syndrome coronavirus and human coronavirus NL63J. Virol.2010841198120510.1128/JVI.01248-0919864379 25.TikellisC.ThomasM.C.Angiotensin-Converting"/>
 <result pre="downregulation of ACE2 by the spike proteins of severe acute" exact="respiratory" post="syndrome coronavirus and human coronavirus NL63J. Virol.2010841198120510.1128/JVI.01248-0919864379 25.TikellisC.ThomasM.C.Angiotensin-Converting Enzyme"/>
 <result pre="of ACE2 by the spike proteins of severe acute respiratory" exact="syndrome" post="coronavirus and human coronavirus NL63J. Virol.2010841198120510.1128/JVI.01248-0919864379 25.TikellisC.ThomasM.C.Angiotensin-Converting Enzyme 2"/>
 <result pre="SARS coronavirus-induced lung injuryNat. Med.20051187587910.1038/nm126716007097 27.Rose-JohnS.The Soluble Interleukin 6 Receptor:" exact="Advanced" post="Therapeutic Options in InflammationClin. Pharm.201710259159810.1002/cpt.782 28.ZhuN.ZhangD.WangW.LiX.YangB.SongJ.ZhaoX.HuangB.ShiW.LuR.et al.A Novel Coronavirus"/>
 <result pre="in InflammationClin. Pharm.201710259159810.1002/cpt.782 28.ZhuN.ZhangD.WangW.LiX.YangB.SongJ.ZhaoX.HuangB.ShiW.LuR.et al.A Novel Coronavirus from Patients with" exact="Pneumonia" post="in China, 2019N. Engl. J. Med.202038272773310.1056/NEJMoa200101731978945 29.ChenI.Y.MoriyamaM.ChangM.F.IchinoheT.Severe Acute Respiratory"/>
 <result pre="Patients with Pneumonia in China, 2019N. Engl. J. Med.202038272773310.1056/NEJMoa200101731978945 29.ChenI.Y.MoriyamaM.ChangM.F.IchinoheT.Severe" exact="Acute" post="Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 InflammasomeFront."/>
 <result pre="with Pneumonia in China, 2019N. Engl. J. Med.202038272773310.1056/NEJMoa200101731978945 29.ChenI.Y.MoriyamaM.ChangM.F.IchinoheT.Severe Acute" exact="Respiratory" post="Syndrome Coronavirus Viroporin 3a Activates the NLRP3 InflammasomeFront. Microbiol.2019105010.3389/fmicb.2019.0005030761102"/>
 <result pre="Pneumonia in China, 2019N. Engl. J. Med.202038272773310.1056/NEJMoa200101731978945 29.ChenI.Y.MoriyamaM.ChangM.F.IchinoheT.Severe Acute Respiratory" exact="Syndrome" post="Coronavirus Viroporin 3a Activates the NLRP3 InflammasomeFront. Microbiol.2019105010.3389/fmicb.2019.0005030761102 30.ZhaoY.ZhaoZ.WangY.ZhouY.MaY.ZuoW.Single-cell"/>
 <result pre="of ACE2, the putative receptor of Wuhan 2019-nCovbioRxiv202010.1101/2020.01.26.919985 31.VargaZ.FlammerA.J.SteigerP.HabereckerM.AndermattR.ZinkernagelA.S.MehraM.R.SchuepbachR.A.RuschitzkaF.MochH.Endothelial cell" exact="infection" post="and endotheliitis in COVID-19Lancet202010.1016/S0140-6736(20)30937-5 32.LamersM.M.BeumerJ.van der VaartJ.KnoopsK.PuschhofJ.BreugemT.I.RavelliR.B.G.Paul van SchayckJ.MykytynA.Z.DuimelH.Q.et"/>
 <result pre="al.SARS-CoV-2 productively infects human gut enterocytesScience202010.1126/science.abc1669 33.WangX.ZhouY.JiangN.ZhouQ.MaW.L.Persistence of intestinal SARS-CoV-2" exact="infection" post="in patients with COVID-19 leads to re-admission after pneumonia"/>
 <result pre="SARS-CoV-2 infection in patients with COVID-19 leads to re-admission after" exact="pneumonia" post="resolvedInt. J. Infect. Dis.202010.1016/j.ijid.2020.04.06332353545 34.ChannappanavarR.PerlmanS.Pathogenic human coronavirus infections: Causes"/>
 <result pre="and consequences of cytokine storm and immunopathologySemin. Immunopathol.20173952953910.1007/s00281-017-0629-x28466096 35.LiH.LiuL.ZhangD.XuJ.DaiH.TangN.SuX.CaoB.SARS-CoV-2 and" exact="viral" post="sepsis: Observations and hypothesesLancet202010.1016/S0140-6736(20)30920-X 36.BikdeliB.MadhavanM.V.JimenezD.ChuichT.DreyfusI.DrigginE.NigoghossianC.D.AgenoW.MadjidM.GuoY.et al.COVID-19 and Thrombotic or"/>
 <result pre="Am. Coll. Cardiol.202010.1016/j.jacc.2020.04.03132311448 37.GattinoniL.CoppolaS.CressoniM.BusanaM.ChiumelloD.Covid-19 Does Not Lead to a â€œTypicalâ€�" exact="Acute" post="Respiratory Distress SyndromeAm. J. Respir. Crit. Care Med.202010.1164/rccm.202003-0817LE 38.CheungC.Y.PoonL.L.NgI.H.LukW.SiaS.F.WuM.H.ChanK.H.YuenK.Y.GordonS.GuanY.et"/>
 <result pre="Coll. Cardiol.202010.1016/j.jacc.2020.04.03132311448 37.GattinoniL.CoppolaS.CressoniM.BusanaM.ChiumelloD.Covid-19 Does Not Lead to a â€œTypicalâ€� Acute" exact="Respiratory" post="Distress SyndromeAm. J. Respir. Crit. Care Med.202010.1164/rccm.202003-0817LE 38.CheungC.Y.PoonL.L.NgI.H.LukW.SiaS.F.WuM.H.ChanK.H.YuenK.Y.GordonS.GuanY.et al.Cytokine"/>
 <result pre="J. Respir. Crit. Care Med.202010.1164/rccm.202003-0817LE 38.CheungC.Y.PoonL.L.NgI.H.LukW.SiaS.F.WuM.H.ChanK.H.YuenK.Y.GordonS.GuanY.et al.Cytokine responses in severe" exact="acute" post="respiratory syndrome coronavirus-infected macrophages in vitro: Possible relevance to"/>
 <result pre="Respir. Crit. Care Med.202010.1164/rccm.202003-0817LE 38.CheungC.Y.PoonL.L.NgI.H.LukW.SiaS.F.WuM.H.ChanK.H.YuenK.Y.GordonS.GuanY.et al.Cytokine responses in severe acute" exact="respiratory" post="syndrome coronavirus-infected macrophages in vitro: Possible relevance to pathogenesisJ."/>
 <result pre="Crit. Care Med.202010.1164/rccm.202003-0817LE 38.CheungC.Y.PoonL.L.NgI.H.LukW.SiaS.F.WuM.H.ChanK.H.YuenK.Y.GordonS.GuanY.et al.Cytokine responses in severe acute respiratory" exact="syndrome" post="coronavirus-infected macrophages in vitro: Possible relevance to pathogenesisJ. Virol.2005797819782610.1128/JVI.79.12.7819-7826.200515919935"/>
 <result pre="al.Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected" exact="Pneumonia" post="in Wuhan, ChinaJAMA20203231061106910.1001/jama.2020.1585 42.CrouseJ.KalinkeU.OxeniusA.Regulation of antiviral T cell responses"/>
 <result pre="in Wuhan, ChinaJAMA20203231061106910.1001/jama.2020.1585 42.CrouseJ.KalinkeU.OxeniusA.Regulation of antiviral T cell responses by" exact="type I" post="interferonsNat. Rev. Immunol.20151523124210.1038/nri380625790790 43.DecrolyE.ImbertI.CoutardB.BouvetM.SeliskoB.AlvarezK.GorbalenyaA.E.SnijderE.J.CanardB.Coronavirus nonstructural protein 16 is a"/>
 <result pre="similar and contrasting approaches to control interferon-stimulated gene responsesmBio20145e01174-1410.1128/mBio.01174-1424846384 47.FriemanM.YountB.HeiseM.Kopecky-BrombergS.A.PaleseP.BaricR.S.Severe" exact="acute" post="respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering"/>
 <result pre="and contrasting approaches to control interferon-stimulated gene responsesmBio20145e01174-1410.1128/mBio.01174-1424846384 47.FriemanM.YountB.HeiseM.Kopecky-BrombergS.A.PaleseP.BaricR.S.Severe acute" exact="respiratory" post="syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear"/>
 <result pre="contrasting approaches to control interferon-stimulated gene responsesmBio20145e01174-1410.1128/mBio.01174-1424846384 47.FriemanM.YountB.HeiseM.Kopecky-BrombergS.A.PaleseP.BaricR.S.Severe acute respiratory" exact="syndrome" post="coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import"/>
 <result pre="factors on the rough endoplasmic reticulum/Golgi membraneJ. Virol.2007819812982410.1128/JVI.01012-0717596301 48.ChangC.-Y.LiuH.M.ChangM.-F.ChangS.C.Middle East" exact="respiratory" post="syndrome coronavirus nucleocapsid protein suppresses type I and type"/>
 <result pre="on the rough endoplasmic reticulum/Golgi membraneJ. Virol.2007819812982410.1128/JVI.01012-0717596301 48.ChangC.-Y.LiuH.M.ChangM.-F.ChangS.C.Middle East respiratory" exact="syndrome" post="coronavirus nucleocapsid protein suppresses type I and type III"/>
 <result pre="membraneJ. Virol.2007819812982410.1128/JVI.01012-0717596301 48.ChangC.-Y.LiuH.M.ChangM.-F.ChangS.C.Middle East respiratory syndrome coronavirus nucleocapsid protein suppresses" exact="type I" post="and type III interferon induction by targeting RIG-I signalingJ."/>
 <result pre="East respiratory syndrome coronavirus nucleocapsid protein suppresses type I and" exact="type III" post="interferon induction by targeting RIG-I signalingJ. Virol.202010.1128/JVI.00099-20 49.ChannappanavarR.FehrA.R.ZhengJ.Wohlford-LenaneC.AbrahanteJ.E.MackM.SompallaeR.McCrayP.B.Jr.MeyerholzD.K.PerlmanS.IFN-I response"/>
 <result pre="49.ChannappanavarR.FehrA.R.ZhengJ.Wohlford-LenaneC.AbrahanteJ.E.MackM.SompallaeR.McCrayP.B.Jr.MeyerholzD.K.PerlmanS.IFN-I response timing relative to virus replication determines MERS coronavirus" exact="infection" post="outcomesJ. Clin. Investig.20191303625363910.1172/JCI126363 50.JingH.SuH.C.New immunodeficiency syndromes that help us"/>
 <result pre="virus replication determines MERS coronavirus infection outcomesJ. Clin. Investig.20191303625363910.1172/JCI126363 50.JingH.SuH.C.New" exact="immunodeficiency" post="syndromes that help us understand the IFN-mediated antiviral immune"/>
 <result pre="Pediatr.20193181582010.1097/MOP.000000000000082731693592 51.DomsA.SanabriaT.HansenJ.N.Altan-BonnetN.HolmG.H.25-Hydroxycholesterol Production by the Cholesterol-25-Hydroxylase Interferon-Stimulated Gene Restricts Mammalian" exact="Reovirus" post="InfectionJ. Virol.20189210.1128/JVI.01047-18 52.LiuS.Y.AliyariR.ChikereK.LiG.MarsdenM.D.SmithJ.K.PernetO.GuoH.NusbaumR.ZackJ.A.et al.Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry"/>
 <result pre="Restricts Mammalian Reovirus InfectionJ. Virol.20189210.1128/JVI.01047-18 52.LiuS.Y.AliyariR.ChikereK.LiG.MarsdenM.D.SmithJ.K.PernetO.GuoH.NusbaumR.ZackJ.A.et al.Interferon-inducible cholesterol-25-hydroxylase broadly inhibits" exact="viral" post="entry by production of 25-hydroxycholesterolImmunity2013389210510.1016/j.immuni.2012.11.00523273844 53.WrenschF.WinklerM.PohlmannS.IFITM proteins inhibit entry"/>
 <result pre="involvement of natural killer cells in the pathogenesis of severe" exact="acute" post="respiratory syndromeAm. J. Clin. Pathol.200412150751110.1309/WPK7Y2XKNF4CBF3R15080302 58.WangF.NieJ.WangH.ZhaoQ.XiongY.DengL.SongS.MaZ.MoP.ZhangY.Characteristics of peripheral lymphocyte"/>
 <result pre="of natural killer cells in the pathogenesis of severe acute" exact="respiratory" post="syndromeAm. J. Clin. Pathol.200412150751110.1309/WPK7Y2XKNF4CBF3R15080302 58.WangF.NieJ.WangH.ZhaoQ.XiongY.DengL.SongS.MaZ.MoP.ZhangY.Characteristics of peripheral lymphocyte subset"/>
 <result pre="of severe acute respiratory syndromeAm. J. Clin. Pathol.200412150751110.1309/WPK7Y2XKNF4CBF3R15080302 58.WangF.NieJ.WangH.ZhaoQ.XiongY.DengL.SongS.MaZ.MoP.ZhangY.Characteristics of" exact="peripheral" post="lymphocyte subset alteration in COVID-19 pneumoniaJ. Infect. Dis.202010.1093/infdis/jiaa150 59.LawH.K.CheungC.Y.NgH.Y.SiaS.F.ChanY.O.LukW.NichollsJ.M.PeirisJ.S.LauY.L.Chemokine"/>
 <result pre="up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cellsBlood20051062366237410.1182/blood-2004-10-416615860669 60.Cervantes-BarraganL.ZustR.WeberF.SpiegelM.LangK.S.AkiraS.ThielV.LudewigB.Control of coronavirus" exact="infection" post="through plasmacytoid dendritic-cell-derived type I interferonBlood20071091131113710.1182/blood-2006-05-02377016985170 61.LeggeK.L.BracialeT.J.Accelerated migration of"/>
 <result pre="human dendritic cellsBlood20051062366237410.1182/blood-2004-10-416615860669 60.Cervantes-BarraganL.ZustR.WeberF.SpiegelM.LangK.S.AkiraS.ThielV.LudewigB.Control of coronavirus infection through plasmacytoid dendritic-cell-derived" exact="type I" post="interferonBlood20071091131113710.1182/blood-2006-05-02377016985170 61.LeggeK.L.BracialeT.J.Accelerated migration of respiratory dendritic cells to the"/>
 <result pre="infection through plasmacytoid dendritic-cell-derived type I interferonBlood20071091131113710.1182/blood-2006-05-02377016985170 61.LeggeK.L.BracialeT.J.Accelerated migration of" exact="respiratory" post="dendritic cells to the regional lymph nodes is limited"/>
 <result pre="of respiratory dendritic cells to the regional lymph nodes is" exact="limited" post="to the early phase of pulmonary infectionImmunity20031826527710.1016/S1074-7613(03)00023-212594953 62.LauY.L.PeirisJ.S.LawH.K.Role of"/>
 <result pre="regional lymph nodes is limited to the early phase of" exact="pulmonary" post="infectionImmunity20031826527710.1016/S1074-7613(03)00023-212594953 62.LauY.L.PeirisJ.S.LawH.K.Role of dendritic cells in SARS coronavirus infectionHong"/>
 <result pre="immune cells in COVID-19 revealed by single-cell RNA sequencingmedRxiv202010.1101/2020.02.23.20026690 65.ChannappanavarR.FehrA.R.VijayR.MackM.ZhaoJ.MeyerholzD.K.PerlmanS.Dysregulated" exact="Type I" post="Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in"/>
 <result pre="revealed by single-cell RNA sequencingmedRxiv202010.1101/2020.02.23.20026690 65.ChannappanavarR.FehrA.R.VijayR.MackM.ZhaoJ.MeyerholzD.K.PerlmanS.Dysregulated Type I Interferon and" exact="Inflammatory" post="Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected MiceCell Host"/>
 <result pre="sequencingmedRxiv202010.1101/2020.02.23.20026690 65.ChannappanavarR.FehrA.R.VijayR.MackM.ZhaoJ.MeyerholzD.K.PerlmanS.Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause" exact="Lethal" post="Pneumonia in SARS-CoV-Infected MiceCell Host Microbe20161918119310.1016/j.chom.2016.01.00726867177 66.DienzO.RudJ.G.EatonS.M.LanthierP.A.BurgE.DrewA.BunnJ.SurattB.T.HaynesL.RinconM.Essential role of"/>
 <result pre="65.ChannappanavarR.FehrA.R.VijayR.MackM.ZhaoJ.MeyerholzD.K.PerlmanS.Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal" exact="Pneumonia" post="in SARS-CoV-Infected MiceCell Host Microbe20161918119310.1016/j.chom.2016.01.00726867177 66.DienzO.RudJ.G.EatonS.M.LanthierP.A.BurgE.DrewA.BunnJ.SurattB.T.HaynesL.RinconM.Essential role of IL-6"/>
 <result pre="in the lungMucosal Immunol.2012525826610.1038/mi.2012.222294047 67.ShinH.S.KimY.KimG.LeeJ.Y.JeongI.JohJ.S.KimH.ChangE.SimS.Y.ParkJ.S.et al.Immune Responses to Middle East" exact="Respiratory" post="Syndrome Coronavirus During the Acute and Convalescent Phases of"/>
 <result pre="the lungMucosal Immunol.2012525826610.1038/mi.2012.222294047 67.ShinH.S.KimY.KimG.LeeJ.Y.JeongI.JohJ.S.KimH.ChangE.SimS.Y.ParkJ.S.et al.Immune Responses to Middle East Respiratory" exact="Syndrome" post="Coronavirus During the Acute and Convalescent Phases of Human"/>
 <result pre="al.Immune Responses to Middle East Respiratory Syndrome Coronavirus During the" exact="Acute" post="and Convalescent Phases of Human InfectionClin. Infect. Dis.20196898499210.1093/cid/ciy59530060038 68.JenkinsM.K.MoonJ.J.The"/>
 <result pre="69.ZhaoJ.ZhaoJ.MangalamA.K.ChannappanavarR.FettC.MeyerholzD.K.AgnihothramS.BaricR.S.DavidC.S.PerlmanS.Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging" exact="Respiratory" post="CoronavirusesImmunity2016441379139110.1016/j.immuni.2016.05.00627287409 70.AhnJ.Y.SohnY.LeeS.H.ChoY.HyunJ.H.BaekY.J.JeongS.J.KimJ.H.KuN.S.YeomJ.S.et al.Use of Convalescent Plasma Therapy in Two"/>
 <result pre="al.Use of Convalescent Plasma Therapy in Two COVID-19 Patients with" exact="Acute" post="Respiratory Distress Syndrome in KoreaJ. Korean Med. Sci.202035e14910.3346/jkms.2020.35.e14932281317 71.SoresinaA.MorattoD.ChiariniM.PaolilloC.BaresiG.FocaE.BezziM.BaronioB.GiacomelliM.BadolatoR.Two"/>
 <result pre="of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute" exact="Respiratory" post="Distress Syndrome in KoreaJ. Korean Med. Sci.202035e14910.3346/jkms.2020.35.e14932281317 71.SoresinaA.MorattoD.ChiariniM.PaolilloC.BaresiG.FocaE.BezziM.BaronioB.GiacomelliM.BadolatoR.Two X-linked"/>
 <result pre="Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress" exact="Syndrome" post="in KoreaJ. Korean Med. Sci.202035e14910.3346/jkms.2020.35.e14932281317 71.SoresinaA.MorattoD.ChiariniM.PaolilloC.BaresiG.FocaE.BezziM.BaronioB.GiacomelliM.BadolatoR.Two X-linked agammaglobulinemia patients"/>
 <result pre="Acute Respiratory Distress Syndrome in KoreaJ. Korean Med. Sci.202035e14910.3346/jkms.2020.35.e14932281317 71.SoresinaA.MorattoD.ChiariniM.PaolilloC.BaresiG.FocaE.BezziM.BaronioB.GiacomelliM.BadolatoR.Two" exact="X-linked agammaglobulinemia" post="patients develop pneumonia as COVID-19 manifestation but recoverPediatr. Allergy"/>
 <result pre="Respiratory Distress Syndrome in KoreaJ. Korean Med. Sci.202035e14910.3346/jkms.2020.35.e14932281317 71.SoresinaA.MorattoD.ChiariniM.PaolilloC.BaresiG.FocaE.BezziM.BaronioB.GiacomelliM.BadolatoR.Two X-linked" exact="agammaglobulinemia" post="patients develop pneumonia as COVID-19 manifestation but recoverPediatr. Allergy"/>
 <result pre="in KoreaJ. Korean Med. Sci.202035e14910.3346/jkms.2020.35.e14932281317 71.SoresinaA.MorattoD.ChiariniM.PaolilloC.BaresiG.FocaE.BezziM.BaronioB.GiacomelliM.BadolatoR.Two X-linked agammaglobulinemia patients develop" exact="pneumonia" post="as COVID-19 manifestation but recoverPediatr. Allergy Immunol.202010.1111/pai.13263 72.QuintiI.LougarisV.MilitoC.CinettoF.PecoraroA.MezzaromaI.MastroianniC.M.TurrizianiO.BondioniM.P.FilippiniM.et al.A"/>
 <result pre="from patients with AgammaglobulinemiaJ. Allergy Clin. Immunol.202010.1016/j.jaci.2020.04.01332333914 73.HuismanW.MartinaB.E.RimmelzwaanG.F.GrutersR.A.OsterhausA.D.Vaccine-induced enhancement of" exact="viral" post="infectionsVaccine20092750551210.1016/j.vaccine.2008.10.08719022319 74.WangQ.ZhangL.KuwaharaK.LiL.LiuZ.LiT.ZhuH.LiuJ.XuY.XieJ.et al.Immunodominant SARS Coronavirus Epitopes in Humans Elicited"/>
 <result pre="Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on" exact="Infection" post="in Non-human PrimatesACS Infect. Dis.2016236137610.1021/acsinfecdis.6b0000627627203 75.WangW.H.LinC.Y.ChangK.UrbinaA.N.AssavalapsakulW.ThitithanyanontA.LuP.L.ChenY.H.WangS.F.A clinical and epidemiological"/>
 <result pre="76.OliveiraR.A.de Oliveira-FilhoE.F.FernandesA.I.BritoC.A.MarquesE.T.TenorioM.C.GilL.H.Previous dengue or Zika virus exposure can drive to" exact="infection" post="enhancement or neutralisation of other flavivirusesMem. Inst. Oswaldo Cruz2019114e19009810.1590/0074-0276019009831411310"/>
 <result pre="ADE from other coronaviruses?Microbes Infect.202022727310.1016/j.micinf.2020.02.00632092539 78.LiuL.WeiQ.LinQ.FangJ.WangH.KwokH.TangH.NishiuraK.PengJ.TanZ.et al.Anti-spike IgG causes severe" exact="acute" post="lung injury by skewing macrophage responses during acute SARS-CoV"/>
 <result pre="causes severe acute lung injury by skewing macrophage responses during" exact="acute" post="SARS-CoV infectionJCI Insight2019410.1172/jci.insight.123158 79.HarzallahI.DebliquisA.DrenouB.Lupus anticoagulant is frequent in patients"/>
 <result pre="Patients with Covid-19N. Engl. J. Med.202010.1056/NEJMc2007575 81.ChengY.ChengG.ChuiC.H.LauF.Y.ChanP.K.NgM.H.SungJ.J.WongR.S.ABO blood group and" exact="susceptibility to" post="severe acute respiratory syndromeJAMA20052931450145110.1001/jama.293.12.1450-c 82.ZhaoJ.YangY.HuangH.-P.LiD.GuD.-F.LuX.-F.ZhangZ.LiuL.LiuT.LiuY.-K.et al.Relationship between the ABO"/>
 <result pre="Engl. J. Med.202010.1056/NEJMc2007575 81.ChengY.ChengG.ChuiC.H.LauF.Y.ChanP.K.NgM.H.SungJ.J.WongR.S.ABO blood group and susceptibility to severe" exact="acute" post="respiratory syndromeJAMA20052931450145110.1001/jama.293.12.1450-c 82.ZhaoJ.YangY.HuangH.-P.LiD.GuD.-F.LuX.-F.ZhangZ.LiuL.LiuT.LiuY.-K.et al.Relationship between the ABO Blood Group"/>
 <result pre="J. Med.202010.1056/NEJMc2007575 81.ChengY.ChengG.ChuiC.H.LauF.Y.ChanP.K.NgM.H.SungJ.J.WongR.S.ABO blood group and susceptibility to severe acute" exact="respiratory" post="syndromeJAMA20052931450145110.1001/jama.293.12.1450-c 82.ZhaoJ.YangY.HuangH.-P.LiD.GuD.-F.LuX.-F.ZhangZ.LiuL.LiuT.LiuY.-K.et al.Relationship between the ABO Blood Group and"/>
 <result pre="to severe acute respiratory syndromeJAMA20052931450145110.1001/jama.293.12.1450-c 82.ZhaoJ.YangY.HuangH.-P.LiD.GuD.-F.LuX.-F.ZhangZ.LiuL.LiuT.LiuY.-K.et al.Relationship between the ABO" exact="Blood" post="Group and the COVID-19 SusceptibilitymedRxiv202010.1101/2020.03.11.20031096 83.GuillonP.ClementM.SebilleV.RivainJ.G.ChouC.F.Ruvoen-ClouetN.Le PenduJ.Inhibition of the"/>
 <result pre="al.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: A single-centered, retrospective, observational studyLancet Respir."/>
 <result pre="and critical appraisalBMJ202036910.1136/bmj.m1328 89.WongR.S.WuA.ToK.F.LeeN.LamC.W.WongC.K.ChanP.K.NgM.H.YuL.M.HuiD.S.et al.Haematological manifestations in patients with severe" exact="acute" post="respiratory syndrome: Retrospective analysisBMJ20033261358136210.1136/bmj.326.7403.135812816821 90.SummerfieldA.AlvesM.RuggliN.de BruinM.G.McCulloughK.C.High IFN-alpha responses associated"/>
 <result pre="critical appraisalBMJ202036910.1136/bmj.m1328 89.WongR.S.WuA.ToK.F.LeeN.LamC.W.WongC.K.ChanP.K.NgM.H.YuL.M.HuiD.S.et al.Haematological manifestations in patients with severe acute" exact="respiratory" post="syndrome: Retrospective analysisBMJ20033261358136210.1136/bmj.326.7403.135812816821 90.SummerfieldA.AlvesM.RuggliN.de BruinM.G.McCulloughK.C.High IFN-alpha responses associated with"/>
 <result pre="Res.20062624825510.1089/jir.2006.26.24816704301 91.KamphuisE.JuntT.WaiblerZ.ForsterR.KalinkeU.Type I interferons directly regulate lymphocyte recirculation and cause" exact="transient" post="blood lymphopeniaBlood20061083253326110.1182/blood-2006-06-02759916868248 92.ZhengM.GaoY.WangG.SongG.LiuS.SunD.XuY.TianZ.Functional exhaustion of antiviral lymphocytes in COVID-19"/>
 <result pre="of antiviral lymphocytes in COVID-19 patientsCell. Mol. Immunol.20201753353510.1038/s41423-020-0402-232203188 93.Giamarellos-BourboulisE.J.NeteaM.G.RovinaN.AkinosoglouK.AntoniadouA.AntonakosN.DamorakiG.GkavogianniT.AdamiM.E.KatsaounouP.et al.Complex" exact="Immune Dysregulation" post="in COVID-19 Patients with Severe Respiratory FailureCell Host Microbe202010.1016/j.chom.2020.04.00932320677"/>
 <result pre="Mol. Immunol.20201753353510.1038/s41423-020-0402-232203188 93.Giamarellos-BourboulisE.J.NeteaM.G.RovinaN.AkinosoglouK.AntoniadouA.AntonakosN.DamorakiG.GkavogianniT.AdamiM.E.KatsaounouP.et al.Complex Immune Dysregulation in COVID-19 Patients with" exact="Severe" post="Respiratory FailureCell Host Microbe202010.1016/j.chom.2020.04.00932320677 94.BarnesB.J.AdroverJ.M.Baxter-StoltzfusA.BorczukA.Cools-LartigueJ.CrawfordJ.M.Dassler-PlenkerJ.GuerciP.HuynhC.KnightJ.S.et al.Targeting potential drivers of"/>
 <result pre="Immunol.20201753353510.1038/s41423-020-0402-232203188 93.Giamarellos-BourboulisE.J.NeteaM.G.RovinaN.AkinosoglouK.AntoniadouA.AntonakosN.DamorakiG.GkavogianniT.AdamiM.E.KatsaounouP.et al.Complex Immune Dysregulation in COVID-19 Patients with Severe" exact="Respiratory" post="FailureCell Host Microbe202010.1016/j.chom.2020.04.00932320677 94.BarnesB.J.AdroverJ.M.Baxter-StoltzfusA.BorczukA.Cools-LartigueJ.CrawfordJ.M.Dassler-PlenkerJ.GuerciP.HuynhC.KnightJ.S.et al.Targeting potential drivers of COVID-19:"/>
 <result pre="cases with COVID-19medRxiv202010.1101/2020.02.26.20028191 96.ChuK.H.TsangW.K.TangC.S.LamM.F.LaiF.M.ToK.F.FungK.S.TangH.L.YanW.W.ChanH.W.et al.Acute renal impairment in coronavirus-associated severe" exact="acute" post="respiratory syndromeKidney Int.20056769870510.1111/j.1523-1755.2005.67130.x15673319 97.KolliasA.KyriakoulisK.G.DimakakosE.PoulakouG.StergiouG.S.SyrigosK.Thromboembolic risk and anticoagulant therapy in"/>
 <result pre="with COVID-19medRxiv202010.1101/2020.02.26.20028191 96.ChuK.H.TsangW.K.TangC.S.LamM.F.LaiF.M.ToK.F.FungK.S.TangH.L.YanW.W.ChanH.W.et al.Acute renal impairment in coronavirus-associated severe acute" exact="respiratory" post="syndromeKidney Int.20056769870510.1111/j.1523-1755.2005.67130.x15673319 97.KolliasA.KyriakoulisK.G.DimakakosE.PoulakouG.StergiouG.S.SyrigosK.Thromboembolic risk and anticoagulant therapy in COVID-19"/>
 <result pre="call for actionBr. J. Haematol.202010.1111/bjh.16727 98.ChenL.LiX.ChenM.FengY.XiongC.The ACE2 expression in human" exact="heart" post="indicates new potential mechanism of heart injury among patients"/>
 <result pre="ACE2 expression in human heart indicates new potential mechanism of" exact="heart" post="injury among patients infected with SARS-CoV-2Cardiovasc. Res.20201161097110010.1093/cvr/cvaa07832227090 99.MagroC.MulveyJ.J.BerlinD.NuovoG.SalvatoreS.HarpJ.Baxter-StoltzfusA.LaurenceJ.Complement associated"/>
 <result pre="patients infected with SARS-CoV-2Cardiovasc. Res.20201161097110010.1093/cvr/cvaa07832227090 99.MagroC.MulveyJ.J.BerlinD.NuovoG.SalvatoreS.HarpJ.Baxter-StoltzfusA.LaurenceJ.Complement associated microvascular injury and" exact="thrombosis" post="in the pathogenesis of severe COVID-19 infection: A report"/>
 <result pre="severe COVID-19 infection: A report of five casesTransl. Res.202010.1016/j.trsl.2020.04.007 100.CastagnoliR.VottoM.LicariA.BrambillaI.BrunoR.PerliniS.RovidaF.BaldantiF.MarsegliaG.L.Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and"/>
 <result pre="COVID-19 infection: A report of five casesTransl. Res.202010.1016/j.trsl.2020.04.007 100.CastagnoliR.VottoM.LicariA.BrambillaI.BrunoR.PerliniS.RovidaF.BaldantiF.MarsegliaG.L.Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents:"/>
 <result pre="infection: A report of five casesTransl. Res.202010.1016/j.trsl.2020.04.007 100.CastagnoliR.VottoM.LicariA.BrambillaI.BrunoR.PerliniS.RovidaF.BaldantiF.MarsegliaG.L.Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A"/>
 <result pre="five casesTransl. Res.202010.1016/j.trsl.2020.04.007 100.CastagnoliR.VottoM.LicariA.BrambillaI.BrunoR.PerliniS.RovidaF.BaldantiF.MarsegliaG.L.Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)" exact="Infection" post="in Children and Adolescents: A Systematic ReviewJAMA Pediatr.202010.1001/jamapediatrics.2020.1467 101.ChenJ.JiangQ.XiaX.LiuK.YuZ.TaoW.GongW.HanJ.J.Individual"/>
 <result pre="Inhibitors and Risk of Covid-19N. Engl. J. Med.202010.1056/NEJMoa2008975 106.ChinnI.K.BlackburnC.C.ManleyN.R.SempowskiG.D.Changes in" exact="primary" post="lymphoid organs with agingSemin. Immunol.20122430932010.1016/j.smim.2012.04.00522559987 107.YagerE.J.AhmedM.LanzerK.RandallT.D.WoodlandD.L.BlackmanM.A.Age-associated decline in T"/>
 <result pre="immunity to influenza virusJ. Exp. Med.200820571172310.1084/jem.2007114018332179 108.Bermejo-MartinJ.F.Martin-LoechesI.RelloJ.AntonA.AlmansaR.XuL.Lopez-CamposG.PumarolaT.RanL.RamirezP.et al.Host adaptive immunity" exact="deficiency" post="in severe pandemic influenzaCrit. Care201014R16710.1186/cc925920840779 109.ThompsonH.L.SmitheyM.J.SurhC.D.Nikolich-ZugichJ.Functional and Homeostatic Impact"/>
 <result pre="in severe pandemic influenzaCrit. Care201014R16710.1186/cc925920840779 109.ThompsonH.L.SmitheyM.J.SurhC.D.Nikolich-ZugichJ.Functional and Homeostatic Impact of" exact="Age-Related" post="Changes in Lymph Node StromaFront. Immunol.2017870610.3389/fimmu.2017.0070628659930 110.ShakerianL.PourpakZ.ShamlouS.DomsgenE.KazemnejadA.DaliliH.NourizadehM.Determining Laboratory Reference"/>
 <result pre="in Different Age Groups of Iranian Healthy IndividualsIran. J. Allergy" exact="Asthma" post="Immunol.20191814315210.18502/ijaai.v18i2.91731066250 111.CarlockM.A.IngramJ.G.ClutterE.F.CecilN.C.RamgopalM.ZimmermanR.K.WarrenW.KleanthousH.RossT.M.Impact of age and pre-existing immunity on the"/>
 <result pre="at low, but not high, doses of virusJ. Virol.2000745460546910.1128/JVI.74.12.5460-5469.200010823850 120.GuptaM.JardelezaM.S.KimI.DurandM.L.KimL.LoboA.M.Varicella" exact="Zoster" post="Virus Necrotizing Retinitis in Two Patients with Idiopathic CD4"/>
 <result pre="Virol.2000745460546910.1128/JVI.74.12.5460-5469.200010823850 120.GuptaM.JardelezaM.S.KimI.DurandM.L.KimL.LoboA.M.Varicella Zoster Virus Necrotizing Retinitis in Two Patients with" exact="Idiopathic" post="CD4 LymphocytopeniaOcul. Immunol. Inflamm.20162454454810.3109/09273948.2015.103437626472486 121.SteeleR.W.BrittonH.A.AndersonC.T.KnikerW.T.Severe combined immunodeficiency with cartilage-hair"/>
 <result pre="in Two Patients with Idiopathic CD4 LymphocytopeniaOcul. Immunol. Inflamm.20162454454810.3109/09273948.2015.103437626472486 121.SteeleR.W.BrittonH.A.AndersonC.T.KnikerW.T.Severe" exact="combined immunodeficiency" post="with cartilage-hair hypoplasa: In vitro response to thymosin and"/>
 <result pre="Two Patients with Idiopathic CD4 LymphocytopeniaOcul. Immunol. Inflamm.20162454454810.3109/09273948.2015.103437626472486 121.SteeleR.W.BrittonH.A.AndersonC.T.KnikerW.T.Severe combined" exact="immunodeficiency" post="with cartilage-hair hypoplasa: In vitro response to thymosin and"/>
 <result pre="HIV202010.1016/S2352-3018(20)30111-9 123.SchulertG.S.ZhangM.FallN.HusamiA.KissellD.HanoshA.ZhangK.DavisK.JentzenJ.M.NapolitanoL.et al.Whole-Exome Sequencing Reveals Mutations in Genes Linked to" exact="Hemophagocytic Lymphohistiocytosis" post="and Macrophage Activation Syndrome in Fatal Cases of H1N1"/>
 <result pre="Mutations in Genes Linked to Hemophagocytic Lymphohistiocytosis and Macrophage Activation" exact="Syndrome" post="in Fatal Cases of H1N1 InfluenzaJ. Infect. Dis.20162131180118810.1093/infdis/jiv55026597256 124.BracagliaC.PrencipeG.De"/>
 <result pre="SARS-CoV-2J. Virol.202010.1128/JVI.00510-20 126.LinM.TsengH.K.TrejautJ.A.LeeH.L.LooJ.H.ChuC.C.ChenP.J.SuY.W.LimK.H.TsaiZ.U.et al.Association of HLA class I with severe" exact="acute" post="respiratory syndrome coronavirus infectionBMC Med. Genet.20034910.1186/1471-2350-4-912969506 127.AndersenK.G.RambautA.LipkinW.I.HolmesE.C.GarryR.F.The proximal origin"/>
 <result pre="Virol.202010.1128/JVI.00510-20 126.LinM.TsengH.K.TrejautJ.A.LeeH.L.LooJ.H.ChuC.C.ChenP.J.SuY.W.LimK.H.TsaiZ.U.et al.Association of HLA class I with severe acute" exact="respiratory" post="syndrome coronavirus infectionBMC Med. Genet.20034910.1186/1471-2350-4-912969506 127.AndersenK.G.RambautA.LipkinW.I.HolmesE.C.GarryR.F.The proximal origin of"/>
 <result pre="126.LinM.TsengH.K.TrejautJ.A.LeeH.L.LooJ.H.ChuC.C.ChenP.J.SuY.W.LimK.H.TsaiZ.U.et al.Association of HLA class I with severe acute respiratory" exact="syndrome" post="coronavirus infectionBMC Med. Genet.20034910.1186/1471-2350-4-912969506 127.AndersenK.G.RambautA.LipkinW.I.HolmesE.C.GarryR.F.The proximal origin of SARS-CoV-2Nat."/>
 <result pre="130.LiW.ShiZ.YuM.RenW.SmithC.EpsteinJ.H.WangH.CrameriG.HuZ.ZhangH.et al.Bats are natural reservoirs of SARS-like coronavirusesScience200531067667910.1126/science.111839116195424 131.MohdH.A.Al-TawfiqJ.A.MemishZ.A.Middle East" exact="Respiratory" post="Syndrome Coronavirus (MERS-CoV) origin and animal reservoirVirol. J.2016138710.1186/s12985-016-0544-027255185 132.PavlovichS.S.LovettS.P.KorolevaG.GuitoJ.C.ArnoldC.E.NagleE.R.KulcsarK.LeeA.Thibaud-NissenF.HumeA.J.et"/>
 <result pre="al.Bats are natural reservoirs of SARS-like coronavirusesScience200531067667910.1126/science.111839116195424 131.MohdH.A.Al-TawfiqJ.A.MemishZ.A.Middle East Respiratory" exact="Syndrome" post="Coronavirus (MERS-CoV) origin and animal reservoirVirol. J.2016138710.1186/s12985-016-0544-027255185 132.PavlovichS.S.LovettS.P.KorolevaG.GuitoJ.C.ArnoldC.E.NagleE.R.KulcsarK.LeeA.Thibaud-NissenF.HumeA.J.et al.The"/>
 <result pre="Response in Bats Displays Distinctive IFN-Stimulated Gene Expression Kinetics with" exact="Atypical" post="RNASEL InductionJ. Immunol.201820020921710.4049/jimmunol.170121429180486 134.BanerjeeA.RapinN.BollingerT.MisraV.Lack of inflammatory gene expression in"/>
 <result pre="al.Dampened NLRP3-mediated inflammation in bats and implications for a special" exact="viral" post="reservoir hostNat. Microbiol.2019478979910.1038/s41564-019-0371-330804542 136.RenR.WuS.CaiJ.YangY.RenX.FengY.ChenL.QinB.XuC.YangH.et al.The H7N9 influenza A virus"/>
 <result pre="special viral reservoir hostNat. Microbiol.2019478979910.1038/s41564-019-0371-330804542 136.RenR.WuS.CaiJ.YangY.RenX.FengY.ChenL.QinB.XuC.YangH.et al.The H7N9 influenza A" exact="virus infection" post="results in lethal inflammation in the mammalian host via"/>
 <result pre="viral reservoir hostNat. Microbiol.2019478979910.1038/s41564-019-0371-330804542 136.RenR.WuS.CaiJ.YangY.RenX.FengY.ChenL.QinB.XuC.YangH.et al.The H7N9 influenza A virus" exact="infection" post="results in lethal inflammation in the mammalian host via"/>
 <result pre="the mammalian host via the NLRP3-caspase-1 inflammasomeSci. Rep.20177762510.1038/s41598-017-07384-528790324 137.WangW.LiG.DeW.LuoZ.PanP.TianM.WangY.XiaoF.LiA.WuK.et al.Zika" exact="virus infection" post="induces host inflammatory responses by facilitating NLRP3 inflammasome assembly"/>
 <result pre="mammalian host via the NLRP3-caspase-1 inflammasomeSci. Rep.20177762510.1038/s41598-017-07384-528790324 137.WangW.LiG.DeW.LuoZ.PanP.TianM.WangY.XiaoF.LiA.WuK.et al.Zika virus" exact="infection" post="induces host inflammatory responses by facilitating NLRP3 inflammasome assembly"/>
 <result pre="assembly and interleukin-1beta secretionNat. Commun.2018910610.1038/s41467-017-02645-329317641 138.CoatesB.M.StarichaK.L.RavindranN.KochC.M.ChengY.DavisJ.M.ShumakerD.K.RidgeK.M.Inhibition of the NOD-Like Receptor" exact="Protein" post="3 Inflammasome Is Protective in Juvenile Influenza A Virus"/>
 <result pre="of the NOD-Like Receptor Protein 3 Inflammasome Is Protective in" exact="Juvenile" post="Influenza A Virus InfectionFront. Immunol.2017878210.3389/fimmu.2017.0078228740490 139.TateM.D.OngJ.D.H.DowlingJ.K.McAuleyJ.L.RobertsonA.B.LatzE.DrummondG.R.CooperM.A.HertzogP.J.MansellA.Reassessing the role of"/>
 <result pre="the role of the NLRP3 inflammasome during pathogenic influenza A" exact="virus infection" post="via temporal inhibitionSci. Rep.201662791210.1038/srep2791227283237 140.ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.YuJ.KangM.SongY.XiaJ.et al.SARS-CoV-2 Viral Load in"/>
 <result pre="role of the NLRP3 inflammasome during pathogenic influenza A virus" exact="infection" post="via temporal inhibitionSci. Rep.201662791210.1038/srep2791227283237 140.ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.YuJ.KangM.SongY.XiaJ.et al.SARS-CoV-2 Viral Load in"/>
 <result pre="influenza A virus infection via temporal inhibitionSci. Rep.201662791210.1038/srep2791227283237 140.ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.YuJ.KangM.SongY.XiaJ.et al.SARS-CoV-2" exact="Viral" post="Load in Upper Respiratory Specimens of Infected PatientsN. Engl."/>
 <result pre="via temporal inhibitionSci. Rep.201662791210.1038/srep2791227283237 140.ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.YuJ.KangM.SongY.XiaJ.et al.SARS-CoV-2 Viral Load in Upper" exact="Respiratory" post="Specimens of Infected PatientsN. Engl. J. Med.20203821177117910.1056/NEJMc200173732074444 141.PeirisJ.S.ChuC.M.ChengV.C.ChanK.S.HungI.F.PoonL.L.LawK.I.TangB.S.HonT.Y.ChanC.S.et al.Clinical"/>
 <result pre="of Infected PatientsN. Engl. J. Med.20203821177117910.1056/NEJMc200173732074444 141.PeirisJ.S.ChuC.M.ChengV.C.ChanK.S.HungI.F.PoonL.L.LawK.I.TangB.S.HonT.Y.ChanC.S.et al.Clinical progression and" exact="viral" post="load in a community outbreak of coronavirus-associated SARS pneumonia:"/>
 <result pre="findingsThorax20045925225610.1136/thorax.2003.01265814985565 143.CaoB.WangY.WenD.LiuW.WangJ.FanG.RuanL.SongB.CaiY.WeiM.et al.A Trial of Lopinavir-Ritonavir in Adults Hospitalized with" exact="Severe" post="Covid-19N. Engl. J. Med.20203821787179910.1056/NEJMoa200128232187464 144.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and chloroquine effectively inhibit"/>
 <result pre="vitroCell Res.20203026927110.1038/s41422-020-0282-032020029 145.GreinJ.OhmagariN.ShinD.DiazG.AspergesE.CastagnaA.FeldtT.GreenG.GreenM.L.LescureF.X.et al.Compassionate Use of Remdesivir for Patients with" exact="Severe" post="Covid-19N. Engl. J. Med.202010.1056/NEJMoa200701632275812 146.WangY.ZhangD.DuG.DuR.ZhaoJ.JinY.FuS.GaoL.ChengZ.LuQ.et al.Remdesivir in adults with"/>
 <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov.2020610.1038/s41421-020-0156-0 152.GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine and azithromycin as a"/>
 <result pre="of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19" exact="infection" post="with oxygen requirement: Results of a study using routinely"/>
 <result pre="Wuhan, ChinaLancet202039549750610.1016/S0140-6736(20)30183-531986264 159.MaudeS.L.LaetschT.W.BuechnerJ.RivesS.BoyerM.BittencourtH.BaderP.VernerisM.R.StefanskiH.E.MyersG.D.et al.Tisagenlecleucel in Children and Young Adults with" exact="B-Cell" post="4Lymphoblastic LeukemiaN. Engl. J. Med.201837843944810.1056/NEJMoa170986629385370 160.LuoP.LiuY.QiuL.LiuX.LiuD.LiJ.Tocilizumab treatment in COVID-19:"/>
 <result pre="Med. Virol.202010.1002/jmv.25897 162.ToniatiP.PivaS.CattaliniM.GarrafaE.RegolaF.CastelliF.FranceschiniF.FocÃ E.AndreoliL.LatronicoN.Tocilizumab for the treatment of severe COVID-19" exact="pneumonia" post="with hyperinflammatory syndrome and acute respiratory failure: A single"/>
 <result pre="E.AndreoliL.LatronicoN.Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory" exact="syndrome" post="and acute respiratory failure: A single center study of"/>
 <result pre="the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and" exact="acute" post="respiratory failure: A single center study of 100 patients"/>
 <result pre="treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute" exact="respiratory" post="failure: A single center study of 100 patients in"/>
 <result pre="ItalyAutoimmun. Rev.202010.1016/j.autrev.2020.10256832376398 163.GrittiG.RaimondiF.RipamontiD.RivaI.LandiF.AlborghettiL.FrigeniM.DamianiM.MicÃ²C.FagiuoliS.et al.Use of siltuximab in patients with COVID-19" exact="pneumonia" post="requiring ventilatory supportmedRxiv202010.1101/2020.04.01.20048561 164.CavalliG.De LucaG.CampochiaroC.Della-TorreE.RipaM.CanettiD.OltoliniC.CastiglioniB.Tassan DinC.BoffiniN.et al.Interleukin-1 blockade with"/>
 <result pre="DinC.BoffiniN.et al.Interleukin-1 blockade with high-dose anakinra in patients with COVID-19," exact="acute" post="respiratory distress syndrome, and hyperinflammation: A retrospective cohort studyLancet"/>
 <result pre="al.Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute" exact="respiratory" post="distress syndrome, and hyperinflammation: A retrospective cohort studyLancet Rheumatol.202010.1016/S2665-9913(20)30127-2"/>
 <result pre="proteins following anti-TNF-alpha therapy in rheumatoid arthritisJ. Immunol.19991631521152810415055 170.HussellT.PennycookA.OpenshawP.J.Inhibition of" exact="tumor" post="necrosis factor reduces the severity of virus-specific lung immunopathologyEur."/>
 <result pre="convalescent plasma and hyperimmune immunoglobulin for the treatment of severe" exact="acute" post="respiratory infections of viral etiology: A systematic review and"/>
 <result pre="plasma and hyperimmune immunoglobulin for the treatment of severe acute" exact="respiratory" post="infections of viral etiology: A systematic review and exploratory"/>
 <result pre="and hyperimmune immunoglobulin for the treatment of severe acute respiratory" exact="infections" post="of viral etiology: A systematic review and exploratory meta-analysisJ."/>
 <result pre="immunoglobulin for the treatment of severe acute respiratory infections of" exact="viral" post="etiology: A systematic review and exploratory meta-analysisJ. Infect. Dis.2015211809010.1093/infdis/jiu39625030060"/>
 <result pre="StudyClin. Infect. Dis.202010.1093/cid/ciaa199 178.MinoiaF.DaviS.HorneA.BovisF.DemirkayaE.AkikusaJ.AyazN.A.Al-MayoufS.M.BaroneP.BicaB.et al.Dissecting the heterogeneity of macrophage activation" exact="syndrome" post="complicating systemic juvenile idiopathic arthritisJ. Rheumatol.201542994100110.3899/jrheum.14126125877504 179.SedaghatZ.KarimiN.Guillain Barre syndrome"/>
 <result pre="Dis.202010.1093/cid/ciaa199 178.MinoiaF.DaviS.HorneA.BovisF.DemirkayaE.AkikusaJ.AyazN.A.Al-MayoufS.M.BaroneP.BicaB.et al.Dissecting the heterogeneity of macrophage activation syndrome complicating" exact="systemic" post="juvenile idiopathic arthritisJ. Rheumatol.201542994100110.3899/jrheum.14126125877504 179.SedaghatZ.KarimiN.Guillain Barre syndrome associated with"/>
 <result pre="178.MinoiaF.DaviS.HorneA.BovisF.DemirkayaE.AkikusaJ.AyazN.A.Al-MayoufS.M.BaroneP.BicaB.et al.Dissecting the heterogeneity of macrophage activation syndrome complicating systemic" exact="juvenile" post="idiopathic arthritisJ. Rheumatol.201542994100110.3899/jrheum.14126125877504 179.SedaghatZ.KarimiN.Guillain Barre syndrome associated with COVID-19"/>
 <result pre="activation syndrome complicating systemic juvenile idiopathic arthritisJ. Rheumatol.201542994100110.3899/jrheum.14126125877504 179.SedaghatZ.KarimiN.Guillain Barre" exact="syndrome" post="associated with COVID-19 infection: A case reportJ. Clin. Neurosci.202010.1016/j.jocn.2020.04.062"/>
 <result pre="and Interferon Therapy for Critically Ill Patients with Middle East" exact="Respiratory" post="Syndrome: A Multicenter Observational StudyClin. Infect. Dis.2020701837184410.1093/cid/ciz54431925415 181.RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.StebbingJ.Baricitinib as"/>
 <result pre="Observational StudyClin. Infect. Dis.2020701837184410.1093/cid/ciz54431925415 181.RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.StebbingJ.Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory diseaseLancet2020395e30e3110.1016/S0140-6736(20)30304-432032529 182.CantiniF.NiccoliL.MatarreseD.NicastriE.StobbioneP.GolettiD.Baricitinib therapy in COVID-19: A pilot study"/>
 <result pre="StudyClin. Infect. Dis.2020701837184410.1093/cid/ciz54431925415 181.RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.StebbingJ.Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="diseaseLancet2020395e30e3110.1016/S0140-6736(20)30304-432032529 182.CantiniF.NiccoliL.MatarreseD.NicastriE.StobbioneP.GolettiD.Baricitinib therapy in COVID-19: A pilot study on"/>
 <result pre="183.ArabiY.M.MandourahY.Al-HameedF.SindiA.A.AlmekhlafiG.A.HusseinM.A.JoseJ.PintoR.Al-OmariA.KharabaA.et al.Corticosteroid Therapy for Critically Ill Patients with Middle East" exact="Respiratory" post="SyndromeAm. J. Respir. Crit. Care Med.201819775776710.1164/rccm.201706-1172OC29161116 184.HoJ.C.OoiG.C.MokT.Y.ChanJ.W.HungI.LamB.WongP.C.LiP.C.HoP.L.LamW.K.et al.High-dose pulse"/>
 <result pre="Med.201819775776710.1164/rccm.201706-1172OC29161116 184.HoJ.C.OoiG.C.MokT.Y.ChanJ.W.HungI.LamB.WongP.C.LiP.C.HoP.L.LamW.K.et al.High-dose pulse versus nonpulse corticosteroid regimens in severe" exact="acute" post="respiratory syndromeAm. J. Respir. Crit. Care Med.20031681449145610.1164/rccm.200306-766OC12947028 185.SoL.K.LauA.C.YamL.Y.CheungT.M.PoonE.YungR.W.YuenK.Y.Development of"/>
 <result pre="184.HoJ.C.OoiG.C.MokT.Y.ChanJ.W.HungI.LamB.WongP.C.LiP.C.HoP.L.LamW.K.et al.High-dose pulse versus nonpulse corticosteroid regimens in severe acute" exact="respiratory" post="syndromeAm. J. Respir. Crit. Care Med.20031681449145610.1164/rccm.200306-766OC12947028 185.SoL.K.LauA.C.YamL.Y.CheungT.M.PoonE.YungR.W.YuenK.Y.Development of a"/>
 <result pre="Care Med.20031681449145610.1164/rccm.200306-766OC12947028 185.SoL.K.LauA.C.YamL.Y.CheungT.M.PoonE.YungR.W.YuenK.Y.Development of a standard treatment protocol for severe" exact="acute" post="respiratory syndromeLancet20033611615161710.1016/S0140-6736(03)13265-512747883 186.SungJ.J.WuA.JoyntG.M.YuenK.Y.LeeN.ChanP.K.CockramC.S.AhujaA.T.YuL.M.WongV.W.et al.Severe acute respiratory syndrome: Report of"/>
 <result pre="Med.20031681449145610.1164/rccm.200306-766OC12947028 185.SoL.K.LauA.C.YamL.Y.CheungT.M.PoonE.YungR.W.YuenK.Y.Development of a standard treatment protocol for severe acute" exact="respiratory" post="syndromeLancet20033611615161710.1016/S0140-6736(03)13265-512747883 186.SungJ.J.WuA.JoyntG.M.YuenK.Y.LeeN.ChanP.K.CockramC.S.AhujaA.T.YuL.M.WongV.W.et al.Severe acute respiratory syndrome: Report of treatment"/>
 <result pre="standard treatment protocol for severe acute respiratory syndromeLancet20033611615161710.1016/S0140-6736(03)13265-512747883 186.SungJ.J.WuA.JoyntG.M.YuenK.Y.LeeN.ChanP.K.CockramC.S.AhujaA.T.YuL.M.WongV.W.et al.Severe" exact="acute" post="respiratory syndrome: Report of treatment and outcome after a"/>
 <result pre="treatment protocol for severe acute respiratory syndromeLancet20033611615161710.1016/S0140-6736(03)13265-512747883 186.SungJ.J.WuA.JoyntG.M.YuenK.Y.LeeN.ChanP.K.CockramC.S.AhujaA.T.YuL.M.WongV.W.et al.Severe acute" exact="respiratory" post="syndrome: Report of treatment and outcome after a major"/>
 <result pre="of influenzaCochrane Database Syst. Rev.2016310.1002/14651858.CD010406.pub2 188.WuC.ChenX.CaiY.XiaJ.ZhouX.XuS.HuangH.ZhangL.ZhouX.DuC.et al.Risk Factors Associated with" exact="Acute" post="Respiratory Distress Syndrome and Death in Patients with Coronavirus"/>
 <result pre="influenzaCochrane Database Syst. Rev.2016310.1002/14651858.CD010406.pub2 188.WuC.ChenX.CaiY.XiaJ.ZhouX.XuS.HuangH.ZhangL.ZhouX.DuC.et al.Risk Factors Associated with Acute" exact="Respiratory" post="Distress Syndrome and Death in Patients with Coronavirus Disease"/>
 <result pre="Syst. Rev.2016310.1002/14651858.CD010406.pub2 188.WuC.ChenX.CaiY.XiaJ.ZhouX.XuS.HuangH.ZhangL.ZhouX.DuC.et al.Risk Factors Associated with Acute Respiratory Distress" exact="Syndrome" post="and Death in Patients with Coronavirus Disease 2019 Pneumonia"/>
 <result pre="Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus" exact="Disease" post="2019 Pneumonia in Wuhan, ChinaJAMA Intern. Med.202010.1001/jamainternmed.2020.0994 189.NIH Covid-19"/>
 <result pre="Distress Syndrome and Death in Patients with Coronavirus Disease 2019" exact="Pneumonia" post="in Wuhan, ChinaJAMA Intern. Med.202010.1001/jamainternmed.2020.0994 189.NIH Covid-19 Treatment GuidelinesAvailable"/>
 <result pre="case reportInt. J. Infect. Dis.20209329729910.1016/j.ijid.2020.03.00332147538 192.WuY.GuoC.TangL.HongZ.ZhouJ.DongX.YinH.XiaoQ.TangY.QuX.et al.Prolonged presence of SARS-CoV-2" exact="viral" post="RNA in faecal samplesLancet Gastroenterol. Hepatol.202010.1016/S2468-1253(20)30083-2 193.MoH.ZengG.RenX.LiH.KeC.TanY.CaiC.LaiK.ChenR.Chan-YeungM.et al.Longitudinal profile"/>
 <result pre="study of the humoral immune response of patients with severe" exact="acute" post="respiratory syndromeJ. Infect. Dis.200619379279510.1086/50046916479513 195.PayneD.C.IblanI.RhaB.AlqasrawiS.HaddadinA.Al NsourM.AlsanouriT.AliS.S.HarcourtJ.MiaoC.et al.Persistence of Antibodies"/>
 <result pre="of the humoral immune response of patients with severe acute" exact="respiratory" post="syndromeJ. Infect. Dis.200619379279510.1086/50046916479513 195.PayneD.C.IblanI.RhaB.AlqasrawiS.HaddadinA.Al NsourM.AlsanouriT.AliS.S.HarcourtJ.MiaoC.et al.Persistence of Antibodies against"/>
 <result pre="Infect. Dis.200619379279510.1086/50046916479513 195.PayneD.C.IblanI.RhaB.AlqasrawiS.HaddadinA.Al NsourM.AlsanouriT.AliS.S.HarcourtJ.MiaoC.et al.Persistence of Antibodies against Middle East" exact="Respiratory" post="Syndrome CoronavirusEmerg. Infect. Dis.2016221824182610.3201/eid2210.16070627332149 196.ChannappanavarR.ZhaoJ.PerlmanS.T cell-mediated immune response to"/>
 <result pre="Dis.200619379279510.1086/50046916479513 195.PayneD.C.IblanI.RhaB.AlqasrawiS.HaddadinA.Al NsourM.AlsanouriT.AliS.S.HarcourtJ.MiaoC.et al.Persistence of Antibodies against Middle East Respiratory" exact="Syndrome" post="CoronavirusEmerg. Infect. Dis.2016221824182610.3201/eid2210.16070627332149 196.ChannappanavarR.ZhaoJ.PerlmanS.T cell-mediated immune response to respiratory"/>
 <result pre="Respiratory Syndrome CoronavirusEmerg. Infect. Dis.2016221824182610.3201/eid2210.16070627332149 196.ChannappanavarR.ZhaoJ.PerlmanS.T cell-mediated immune response to" exact="respiratory" post="coronavirusesImmunol. Res.20145911812810.1007/s12026-014-8534-z24845462 197.TangF.QuanY.XinZ.T.WrammertJ.MaM.J.LvH.WangT.B.YangH.RichardusJ.H.LiuW.et al.Lack of peripheral memory B cell"/>
 <result pre="cell-mediated immune response to respiratory coronavirusesImmunol. Res.20145911812810.1007/s12026-014-8534-z24845462 197.TangF.QuanY.XinZ.T.WrammertJ.MaM.J.LvH.WangT.B.YangH.RichardusJ.H.LiuW.et al.Lack of" exact="peripheral" post="memory B cell responses in recovered patients with severe"/>
 <result pre="peripheral memory B cell responses in recovered patients with severe" exact="acute" post="respiratory syndrome: A six-year follow-up studyJ. Immunol.20111867264726810.4049/jimmunol.090349021576510 198.XiangF.WangX.HeX.PengZ.YangB.ZhangJ.ZhouQ.YeH.MaY.LiH.et al.Antibody"/>
 <result pre="memory B cell responses in recovered patients with severe acute" exact="respiratory" post="syndrome: A six-year follow-up studyJ. Immunol.20111867264726810.4049/jimmunol.090349021576510 198.XiangF.WangX.HeX.PengZ.YangB.ZhangJ.ZhouQ.YeH.MaY.LiH.et al.Antibody Detection"/>
 <result pre="Res.2017137829210.1016/j.antiviral.2016.11.00627840203 200.ChenH.HouJ.JiangX.MaS.MengM.WangB.ZhangM.ZhangM.TangX.ZhangF.et al.Response of memory CD8+ T cells to severe" exact="acute" post="respiratory syndrome (SARS) coronavirus in recovered SARS patients and"/>
 <result pre="200.ChenH.HouJ.JiangX.MaS.MengM.WangB.ZhangM.ZhangM.TangX.ZhangF.et al.Response of memory CD8+ T cells to severe acute" exact="respiratory" post="syndrome (SARS) coronavirus in recovered SARS patients and healthy"/>
 <result pre="al.Response of memory CD8+ T cells to severe acute respiratory" exact="syndrome" post="(SARS) coronavirus in recovered SARS patients and healthy individualsJ."/>
 <result pre="in SARS-recovered patientsVirology200635146647510.1016/j.virol.2006.03.03616690096 203.YangL.T.PengH.ZhuZ.L.LiG.HuangZ.T.ZhaoZ.X.KoupR.A.BailerR.T.WuC.Y.Long-lived effector/central memory T-cell responses to severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS"/>
 <result pre="SARS-recovered patientsVirology200635146647510.1016/j.virol.2006.03.03616690096 203.YangL.T.PengH.ZhuZ.L.LiG.HuangZ.T.ZhaoZ.X.KoupR.A.BailerR.T.WuC.Y.Long-lived effector/central memory T-cell responses to severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patientsClin."/>
 <result pre="patientsVirology200635146647510.1016/j.virol.2006.03.03616690096 203.YangL.T.PengH.ZhuZ.L.LiG.HuangZ.T.ZhaoZ.X.KoupR.A.BailerR.T.WuC.Y.Long-lived effector/central memory T-cell responses to severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) S antigen in recovered SARS patientsClin. Immunol.200612017117810.1016/j.clim.2006.05.00216781892"/>
 <result pre="204.YangL.PengH.ZhuZ.LiG.HuangZ.ZhaoZ.KoupR.A.BailerR.T.WuC.Persistent memory CD4+ and CD8+ T-cell responses in recovered severe" exact="acute" post="respiratory syndrome (SARS) patients to SARS coronavirus M antigenJ."/>
 <result pre="memory CD4+ and CD8+ T-cell responses in recovered severe acute" exact="respiratory" post="syndrome (SARS) patients to SARS coronavirus M antigenJ. Gen."/>
 <result pre="CD4+ and CD8+ T-cell responses in recovered severe acute respiratory" exact="syndrome" post="(SARS) patients to SARS coronavirus M antigenJ. Gen. Virol.2007882740274810.1099/vir.0.82839-017872527"/>
 <result pre="Immunol.20201711312210.1038/s41423-019-0359-131969685 207.ZhaoJ.ZhaoJ.PerlmanS.T cell responses are required for protection from clinical" exact="disease" post="and for virus clearance in severe acute respiratory syndrome"/>
 <result pre="protection from clinical disease and for virus clearance in severe" exact="acute" post="respiratory syndrome coronavirus-infected miceJ. Virol.2010849318932510.1128/JVI.01049-1020610717 208.ChannappanavarR.FettC.ZhaoJ.MeyerholzD.K.PerlmanS.Virus-specific memory CD8 T"/>
 <result pre="from clinical disease and for virus clearance in severe acute" exact="respiratory" post="syndrome coronavirus-infected miceJ. Virol.2010849318932510.1128/JVI.01049-1020610717 208.ChannappanavarR.FettC.ZhaoJ.MeyerholzD.K.PerlmanS.Virus-specific memory CD8 T cells"/>
 <result pre="clinical disease and for virus clearance in severe acute respiratory" exact="syndrome" post="coronavirus-infected miceJ. Virol.2010849318932510.1128/JVI.01049-1020610717 208.ChannappanavarR.FettC.ZhaoJ.MeyerholzD.K.PerlmanS.Virus-specific memory CD8 T cells provide"/>
 <result pre="memory CD8 T cells provide substantial protection from lethal severe" exact="acute" post="respiratory syndrome coronavirus infectionJ. Virol.201488110341104410.1128/JVI.01505-1425056892 Figure 1 (a) Immune"/>
 <result pre="CD8 T cells provide substantial protection from lethal severe acute" exact="respiratory" post="syndrome coronavirus infectionJ. Virol.201488110341104410.1128/JVI.01505-1425056892 Figure 1 (a) Immune response"/>
 <result pre="T cells provide substantial protection from lethal severe acute respiratory" exact="syndrome" post="coronavirus infectionJ. Virol.201488110341104410.1128/JVI.01505-1425056892 Figure 1 (a) Immune response to"/>
 <result pre="A hypothetical vicious circle between distinct pathogenic mechanisms associated with" exact="disease" post="worsening. vaccines-08-00224-t001_Table 1Table 1 Critical mechanisms of potential relevance"/>
 <result pre="1 Critical mechanisms of potential relevance as targets of therapies." exact="Immunologic" post="Mechanism Involved in Antiviral Response Hypothesized Defects Associated with"/>
 <result pre="Immunologic Mechanism Involved in Antiviral Response Hypothesized Defects Associated with" exact="Severe" post="Infection Effect on Antiviral Response Proposal of Possible Therapeutic"/>
 <result pre="Mechanism Involved in Antiviral Response Hypothesized Defects Associated with Severe" exact="Infection" post="Effect on Antiviral Response Proposal of Possible Therapeutic Actions"/>
 <result pre="Innate immunity Early production of IFNs Defects in IFN cascade." exact="Susceptibility to" post="severe course of herpes, VZV and flu Early Type-I"/>
 <result pre="antiviral medications Activity of natural killer cells Defective cytotoxic functions" exact="Primary" post="hemophagocytic lymphohistiocytosis. Susceptibility to herpetic viruses. Administration of third-party"/>
 <result pre="medications Activity of natural killer cells Defective cytotoxic functions Primary" exact="hemophagocytic lymphohistiocytosis." post="Susceptibility to herpetic viruses. Administration of third-party NK. Blockade"/>
 <result pre="of natural killer cells Defective cytotoxic functions Primary hemophagocytic lymphohistiocytosis." exact="Susceptibility to" post="herpetic viruses. Administration of third-party NK. Blockade of lymphohistiocytosis"/>
 <result pre="Blockade of lymphohistiocytosis associated cytokine storm Late activation of neutrophils" exact="Increased" post="inflammasome signaling Possible enhancement of inflammatory response to viruses"/>
 <result pre="Adaptive immunity Recruitment and expansion of virus-specific CD4 T cells" exact="Combined" post="immunodeficiencies with defects in the generation of T-cell and"/>
 <result pre="with defects in the generation of T-cell and B-cell repertoire" exact="Susceptibility to" post="severe infections from various kind of viruses Administration of"/>
 <result pre="the generation of T-cell and B-cell repertoire Susceptibility to severe" exact="infections" post="from various kind of viruses Administration of third-party specific"/>
 <result pre="T-cell receptor Defective response to most viruses Production of antibodies" exact="Agammaglobulinemia" post="Not strictly required to overcome the infection. Reduced memory"/>
 <result pre="of antibodies Agammaglobulinemia Not strictly required to overcome the infection." exact="Reduced" post="memory response to new challenges from the same virus"/>
 <result pre="virus Hyper-immune plasma from recovered subjects Production of ADE-capable antibodies" exact="Increased" post="spreading of infection, even to cells not expressing ACE2"/>
 <result pre="ACE2 Administration of high dose donor immunoglobulins Production of autoantibodies" exact="Vasculitis" post="Vascular protection; anticoagulation; immunosuppression"/>
 <result pre="Administration of high dose donor immunoglobulins Production of autoantibodies Vasculitis" exact="Vascular" post="protection; anticoagulation; immunosuppression"/>
</results>
